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Parkinson's disease (PD) is a debilitating neurodegenerative disease affecting the elderly 
population. It has been a challenge elucidating the molecular mechanisms underlying the 
selective loss of dopaminergic neurons, since much of the etiopathology of the disease remains 
unknown. Genetic studies of the familial PD cases have yielded a handful of Parkinson's related 
loci- the PARK loci, that have attributed most of the molecular knowledge we have. In this study, I 
investigated the role of PARK15- the FBXO7 protein in neurons at the molecular, cellular and 
histological level. I found that FBXO7 interacts with the microtubule associated protein 1B light 
chain 1 (MAP1B LC1) independently of its E3-ligase activity. Furthermore, FBXO7 is an important 
factor in mitochondrial maintenance and it is essential for neuronal morphogenesis. Quantitative 
mass spectrometry supported this data and further expanded the involvement of FBXO7 in 
multiple cellular mechanisms such as DNA repair and vesicular transport. Additionally, I examined 
the effect of knockout of Fbxo7 in the forebrain in Mus musculus, and observed a generalized 
brain damage without the loss of cortical neurons. Taken together, these findings further broaden 





1.  Introduction 
1.1. Parkinson's Disease 
Ever since humanity discovered the healing benefit of plants, the goal of medicine has been 
to increase the life expectancy and decrease pain and suffering. In modern history, the 
introduction of penicillin, vaccinations and advances in health care have led to an unprecedented 
life expectancy highs, largely due to decrease in child mortality ( Jamison et al., 2013). The new 
objective of medicine has then shifted to increase the quality of life of the ever-growing elderly 
population.  
Parkinson's disease (PD) is the most common neurodegenerative motor disorder (Van Laar 
and Berman, 2009), and it is estimated that it affects about 1% of the population older than 65 
and 4% of the population older than 80 years (de Lau and Breteler, 2006). The major risk factor of 
PD is aging and it was grossly considered sporadic in its etiopathology (de Lau and Breteler, 2006) 
until 1983, when a group of young people developed PD-like symptoms after intravenous 
injection of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP)-containing drugs (Langston et 
al., 1983; Shulman et al., 2011). The patients presented very severe form of parkinsonism, 
substantiated by stiffness and immobility, fixed stare (bradykinesia), "pill -rolling" tremor and 
postural instability (Langston et al., 1983). It was predicted that the patients had selective loss of 
dopaminergic neurons in substantia nigra- the major histopathological hallmark of PD, next to 
Lewy body pathology (Braak et al., 2003; Langston et al., 1983). The earliest genetic studies, 
showing that PD may also be caused by hereditary mutations in these genes, were performed in 
1996, identifying the first monogenetic PARK1/4 locus (4q21) also known as SNCA, encoding the 
synuclein protein and the major constituent of Lewy Bodies (Polymeropoulos et al., 1996; 
Shulman et al., 2011; Wakabayashi et al., 1998). Lewy bodies are intracellular aggregation of 
proteins into fibrils, known as inclusions, where the synuclein fibrils are accompanied by many 
other proteins including FBXO7 and ubiquitin (Engelender, 2008; Zhao et al., 2013).  In the 
following years, a total of 18 PD related loci were identified accounting for around 10% of the 
total PD cases (Klein and Westenberger, 2012). These encode most notably Parkin, PTEN-induced 
putative kinase 1 (PINK1), DJ-1, Leucine-rich repeat kinase 2 (LRRK2), ATPase 13A2 (ATP13A2), F-
box protein other 7 (FBXO7) and the vacuolar protein sorting-associated protein 35 (VPS35) 
which together defined the familial PD as genetically heterogenous (Klein and Schlossmacher, 
2007; Klein and Westenberger, 2012). Even though these cases account for only a small fraction 
of the total epidemiology of PD, studying these genes has granted us invaluable insights into the 





1.2. The Parkinsonian pyramidal syndrome  
Mutations in the FBXO7 gene were first recognized by Shojaee et al. where the authors 
performed a genome-wide linkage analysis on a large Iranian pedigree with Parkinsonian-
pyramidal syndrome (PPS) (Shojaee et al., 2008). The exact onset of the disease is not specified 
but the clinical symptoms are well characterized: all patients exhibited pyramidal syndromes such 
as Babinski sign, spasticity in lower limbs and hyperactive deep tendon reflexes  (Shojaee et al., 
2008). Extrapyramidal symptoms such as rigidity and bradykinesia, characteristic of parkinsonism, 
have evolved at later stages and not in all patients and none of the patients had tremor or 
dementia (Shojaee et al., 2008). Since PPS is a rarely developed syndrome and the fact that the 
affected offspring was from a consanguineous family, it was suggested that the mutation ( R378G) 
segregates with the PPS in an autosomal recessive inheritance pattern (Shojaee et al., 2008). 
Further mutations on FBXO7 were identified by Di Fonzo et al.: the R498X truncating mutation in 
a Dutch family and the compound heterozygous mutation at the splice-site IVS7 + 1G/T together 
with the missense T22M mutation in an Italian family (Di Fonzo et al., 2009). Both mutations 
resulted in early-onset parkinsonism- 10 and 13 years of age for the Dutch family and 18 and 19 
years for the Italian family, followed by pyramidal signs and no cognitive disturbances (Di Fonzo et 
al., 2009). Further cases of the R498X mutation were reported with similar clinical symptoms but 
these did not exhibit pyramidal signs (Paisan-Ruiz et al., 2010; Yalcin-Cakmakli et al., 2014). Lastly, 
two single nucleotide polymorphisms (SNPs) of the Fbxo7 gene were identified in a Taiwanese 
cohort with early onset of PD- the Y52C and the M115I, but clinical data on these is sparse (Chen 
et al., 2014). Interestingly, a new L34R mutation in a Turkish family was shown to lead to a 
classical late onset PD (Lohmann et al., 2015).   
 All of the patients' clinical reports include early-onset parkinsonism-like motor 
dysfunctions together with pyramidal signs (Table 1.1). A striking distinction between PPS and PD 
patients is that non-motor features of PPS patients were significantly different from the classical 
PD. In classical PD, the prodromal features such as disturbances in the rapid eye movement (REM) 
sleeping behavior, loss of olfaction, autonomic disturbances, depression and anxiety are usually 
followed by cognitive impairment such as dementia as well as verbal and attention deficits as the 
disease progresses (Goldman and Postuma, 2014). Patients with PPS have a large spectrum of 
non-motor disturbances, ranging from none to mental retardation (Shojaee et al., 2008; Yalcin-







Table 1.1  List of patients with parkinsonian pyramidal syndrome with the corresponding 
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1.3. Fbxo7 and FBXO7 
The variance in clinical symptoms in PPS patients can be attributed to the fact that they are 
elicited by different mutations in the Fbxo7 gene, all located within different functional domains 
of the protein (Fig. 1.1) (Nelson et al., 2013).   
 
Fig. 1.1  The Fbxo7 locus, transcript and pathological mutations  
Schematic representation of the nine exons of the Fbxo7 gene in blue boxes and the primary protein 
structure with its different domains. The pathological mutations and SNP along the protein and the gene 
(splicing mutation) are indicated with red arrows. (UbR= ubiquitin related; Cdk6 bd= cyclin-dependent 
kinase 6 binding domain; FP= FBXO7/PI31; PRR= Proline rich) 
The Fbxo7 locus is on the long arm of chromosome 22 and it comprises of nine exons, 
further transcribed into three functional isoforms (Nelson et al., 2013). Isoform 1 has the longest 
mRNA transcript encoded by 552 amino acids and it is expressed in all types of human and murine 
tissue: brain, heart, kidney, liver, lung, spleen, skeletal muscle, pancreas and the placenta (Vingill 
et al., 2016; Winston et al., 1999). The functional domains were discovered chronologically and 
are involved in different cellular mechanisms, including cell cycle, proteasome regulation, 
ubiquitination and mitophagy (Burchell et al., 2013; Cenciarelli et al., 1999; Kirk et al., 2008; 
Laman et al., 2005; Vingill et al., 2016) 
1.3.1. FBXO7 functions in cell cycle and proteostasis 
While studying the cell cycle mechanisms in yeast, Bai et al. identified Skp1 as the direct 
interactor of mitotic cyclin F through a novel evolutionary conserved 40 amino acid motif the F-
box (Fig. 1.1) (Bai et al., 1996). The authors stressed the importance of the precise timing and the 
balance of expression and degradation of the cell cycle related proteins in order to ensure the 
orchestration of the cell cycle transitions (Bai et al., 1996). The spatial and temporal control is 
largely accomplished by the post-translational ubiquitination of an array of proteins, and thus the 
binding of Skp1 to the F-box domain of proteins was identified as the link between the ubiquitin 





FBXO7 was firstly identified simultaneously by two research groups as part of a family of F-
box proteins whose main role was constituting one of the subunits of the Skp1-cul1-F-box protein 
(SCF) E3 ubiquitin ligase (Fig. 1.2) (Cenciarelli et al., 1999; Winston et al., 1999). Within a short 
span of time, it was recognized that FBXO7 has not only SCF but also non-SCF functions, where 
the latter is implicated in cell-cycle progression (Laman et al., 2005). It was found that FBXO7 
interacts with the D cyclin/cdk6 complexes through its CDK6 domain rather more as an assembly 
protein than an E3 ubiquitin ligase subunit (Fig. 1.1) (Laman et al., 2005). Through this interaction, 
FBXO7 was inaugurated as a potential proto-oncogene, since its overexpression leads to 
enhancement of the D cyclin/cdk6 assembly and subsequently activation, ultimately leading to 
transforming healthy cells into malignant (Laman et al., 2005). 
 
Fig. 1.2  The FBXO7-SCF ligase complex 
The FBXO7-SCF ligase complex comprises of four major subunits - Rbx1, culllin1, Skp1 and FBXO7. The PRR 
domain on the FBXO7 protein recruits the substrate and the F-box domain is indispensable for its 
interaction with Skp1. Upon the assembly of the E2 and the E3 complex, the substrate can get mono-, multi-







FBXO7's function as the substrate recognition subunit of the SCF E3 ubiquitin ligase was 
reported in the canonical ubiquitination by the UPS of the Hepatoma Up-regulated Protein 
(HURP) (Hsu et al., 2004). The recruitment and ubiquitination of the HURP required its 
phosphorylation and intact FBXO7 C-terminal harboring the proline rich (PRR) domain, indicating 
that the PRR domain is the substrate-binding domain of the protein (Fig. 1.2) (Hsu et al., 2004). 
Canonical ubiquitination leads to the proteasomal degradation of the ubiquitin-tagged proteins by 
the UPS in five steps, starting with ubiquitin activation in adenosine triphosphate (ATP)-
dependent manner by an E1 enzyme (Fig. 1.3 i) (Yi and Ehlers, 2007). Next, ubiquitin is conjugated 
to an E2 conjugating enzyme (Fig. 1.3 ii) that can then associate with E3 ubiquitin ligases, 
transferring the ubiquitin moiety onto a substrate (Fig. 1.3 iii) (Yi and Ehlers, 2007). Next, the 
ubiquitin tagged protein is degraded by the proteasome again in ATP-dependent manner (Fig. 1.3 
vi) and finally, ubiquitin is recycled with the help of deubiquitinases (DUB) (Fig. 1.3 v) (Yi and 
Ehlers, 2007).  
 
Fig. 1.3  Canonical ubiquitination cycle and the ubiquitin proteasome system 
Ub (ubiquitin) is activated by an E1 enzyme utilizing the hydrolysis of ATP (i) and then conjugated to an E2 
enzyme (ii). The E2 enzyme forms a complex with the E3 ubiquitin ligase, leading to substrate ubiquitination 





Ubiquitination can take different forms depending on the type of E2 enzyme, namely, 
mono-, multi-mono or polyubiquitination (Fig. 1.2) (Komander, 2009). When a single ubiquitin 
molecule is ligated to a lysine (Lys) residue on the substrate (mono-ubiquitination) or to multiple 
lysine residues (multi-mono-ubiquitination), it can trigger a cascade leading to lysosomal 
degradation of cell surface receptors or DNA damage response (Komander, 2009). 
Polyubiquitination on the other hand, can be much more diverse in its functions, since the 
ubiquitin polymers can be assembled differently depending on the type of lysine linkage 
(Komander, 2009). For example, Lys48 and Lys11 polyubiquitination leads to proteasomal 
degradation (canonical ubiquitination) (Fig. 1.3); Lys11 has further non-degradative functions in 
cell cycle and endoplasmic reticulum-associated degradation (ERAD) pathways; Lys 48 
polyubiquitination plays role in endocytosis, DNA-damage response and cytokine signaling and so 
on (Komander, 2009). This enormous complexity and control of substrate ubiquitination is 
responsible for the vastness of the acquired physiological roles of the modified protein.  
1.3.2. Function of FBXO7 in proteasomal stability 
Further research revealed a novel function of FBXO7 in the UPS, not just as part of E3 
ubiquitin ligase, but also as regulator of proteasome activity (Bader et al., 2011; Kirk et al., 2008; 
Vingill et al., 2016). The first report linking FBXO7 with the proteasome inhibitor PI31, unraveled a 
new domain on the FBXO7 protein that was responsible for the  homodimerization of FBXO7 as 
well as the heterodimerization of FBXO7 with the PI31, and was therefore named FP (FBXO7/PI31) 
domain (Fig. 1.1) (Kirk et al., 2008). This interaction had no effects on the stability of PI31, so it 
was argued that PI31 is not a substrate for the FBXO7-SCF complex (Kirk et al., 2008).  The 
functional significance of this interaction was later shown in spermatogenesis in Drosophila 
melanogaster, where the fly orthologue of the FBXO7- the Nutcracker regulates the stability of 
DmPI31 in a positive fashion and mutations in the nutcracker resulted in male fly sterility (Bader 
et al., 2011).  
The role and the molecular mechanism in which FBXO7 regulates the proteasome activity in 
mammals, were elucidated recently by Vingill et al. The authors found that FBXO7 interacts 
directly with the proteasomal subunit 2 (PSMA2) through its ubiquitin related domain (UbRD) 
(Fig. 1.1) leading to its Lys63 polyubiquitination (Vingill et al., 2016). The functional significance of 
this interaction is that, since FBXO7 facilitates the 20S core particle assembly with the 19S 
regulatory particles, mutations in Fbxo7 result in net decrease in proteasomal activity due to 





proteasomal activity is then further reflected into the UPS inability to efficiently degrade 
ubiquitinated proteins (Vingill et al., 2016). 
1.3.3. Functions of FBXO7 in mitophagy: the PINK1, Parkin and FBXO7 interaction 
The 1-88 amino acid stretch on the FBXO7 partially coinciding with the UbRD (Fig. 1.1), was 
found to be the binding site for two of the main mitophagy initiators and consecutively PARK loci 
encoding for PINK1 and Parkin (Burchell et al., 2013). Mitophagy is a part of the mitochondrial 
quality control mechanism together with mitochondrial dynamics and biogenesis (Scarffe et al., 
2014). The delicate orchestration of mitochondrial fission, fusion, trafficking, degradation and 
biogenesis ensures the optimal ATP synthesis at simultaneously the lowest reactive oxygen 
species (ROS) generation rate (Scarffe et al., 2014). This balance however, can be disrupted by the 
introduction of mitochondrial stress, which can be initiated genetically or epigenetically (aging, 
environment), leading to an increase in ROS production (Youle and van der Bliek, 2012). These 
highly reactive radicals can disrupt the covalent bonds within molecules leading to DNA, protein 
and lipid aberrations (Youle and van der Bliek, 2012). The cell has evolved a whole battery of 
protective mechanisms in response to the degree of injury, for example: damaged proteins within 
mitochondria are repaired by mitochondrial proteases; proteins located on the outer 
mitochondrial membrane are kept under surveillance and regulated by the UPS and finally, if the 
mitochondrial damage cannot be handled, mitochondria will be catabolized through mitophagy 
(Campello et al., 2014). Mitophagy is a specialized process, in which unhealthy mitochondria 
destined for degradation are sequestered, transported and fused with the lysosomes (Campello et 
al., 2014). Even though there are many proteins involved in this copious process, two stand out 
because of their relevance in human disease: PINK1 and Parkin.  Mutations in Parkin (PARK2) and 
PINK1 (PARK6) account for the highest and second highest prevalence of autosomal -recessive PD 
respectively (Scarffe et al., 2014). The general mechanism in which these two proteins interact to 
mediate mitophagy, starts with PINK1 scouting for mitochondria with depolarized inner 
membranes (Fig. 1.4) (Narendra et al., 2012). PINK1 is a serine/threonine protein kinase, that is 
synthesized in the cytoplasm, but is then transported to mitochondria, where under basal, 
healthy conditions is cleaved by mitochondrial proteases (Fig. 1.4 A) (Narendra et al., 2012; 
Valente et al., 2004; Whitworth et al., 2008). Upon reduction of the mitochondrial membrane 
potential (m), PINK1 accumulates on the outer mitochondrial membrane (OMM) and activates 
the E3 ubiquitin ligase Parkin by phosphorylating it within Parkin's ubiquitin-like domain (Ubl) (Fig. 
1.4 B) (Kondapalli et al., 2012; Narendra et al., 2010). Once activated, Parkin then ubiquitinates a 





(Mfn2) and Miro1 (Fig. 1.4 B) (Gegg et al., 2010; Sarraf et al., 2013). The ubiquitination of the 
Mfn1 and 2 arrests mitochondrial fusion, ensuring that damaged mitochondria will be prevented 
to fuse back into the healthy network of mitochondria (Fig. 1.4 B) (Narendra et al., 2012). 
Furthermore, mitochondrial transport towards the plus (+) end is halted by the degradation of 
Miro1, speculatively in order to ensure that unhealthy mitochondria cannot be transported to 
areas with high bio-energetic demands such as the axonal terminus (Narendra et al., 2012).  
 
Fig. 1.4  PINK1/Parkin dependent mitochondrial maintenance and mitophagy 
 (A) Healthy mitochondria with regular m (i) express proteinases that degrade PINK1 (ii). Mfn1 and 2 
remain intact on the outer mitochondrial membrane OMM (iii) allowing for the fusion of mitochondria to 
the mitochondrial network (vi). (B) Depolarized mitochondria (i) accumulate PINK1 on their OOM, leading to 
the translocation of FBXO7 from the cytoplasm to the OOM, which acts as a scaffold protein for the 
formation of the PINK1-Parkin complex (iii). PINK1 then phosphorylates the E3 ligase Parkin, thus activating 
it (vi). Activated Parkin then ubiquitinates  (Ub=ubiquitin) multiple proteins including Mfn1 and 2 (v), leading 





There are many pieces of the puzzle missing in explaining how exactly mitophagy is 
mediated by PINK1 and Parkin. FBXO7 appears to be one of them, since it is required for the 
translocation of Parkin to depolarized mitochondria by acting as a scaffold protein for the 
interaction between PINK1 and Parkin (Fig. 1.4 B) (Burchell et al., 2013). As mentioned previously, 
this interaction can be mapped to the N-terminus of FBXO7 and more specifically to the Ubiquitin-
like  (Ubl) domain for Parkin and the interaction with PINK1 spans not only the Ubl domain but the 
whole stretch up to the CDK6 binding domain (Burchell et al., 2013). The involvement of FBXO7 in 
mitochondrial quality control was further substantiated by two independently working groups, 
where the pathological mutants of Fbxo7 were shown to aggregate in mitochondria, inhibit 
mitophagy, lead to increased generation of ROS at expense of decreased m and ATP 
production (Delgado-Camprubi et al., 2017; Zhou et al., 2015). 
1.4. The Cytoskeleton: stability and dynamics  
Microtubules (MTs) play paramount role in cellular architecture, motility, division and 
organellar transport (Mandelkow and Mandelkow, 1995). Since neurons have highly polarized 
morphology that is required for their function in signal transmission, microtubule dynamics and 
stabilization is of particular importance (Benitez-King et al., 2004).  Furthermore, during 
synaptogenesis in embryonic development and plasticity, extracellular cues guide the growth 
cone through the intercellular space until it reaches its target, ensuring the correct connectivity 
pattern (Mattson et al., 1988). This axon guidance and motility is achieved because of the 
dynamic nature of microtubules (Gonzalez-Billault et al., 2001).  
 Microtubules are assembled through the polymerization of  and  tubulin homodimers 
into heterodimers and protofilaments, where 13 protofilaments form a hollow cylinder (Fig. 1.5) 
(Mohri, 1968). The heterodimers always polymerize such that the -tubulin subunit binds to the 
-tubulin subunit of another heterodimer, rendering the microtubules themselves as polar 
structures with a slow-growing minus end and a fast growing plus end (Fig. 1.5) (Benitez-King et 
al., 2004). Therefore, the dynamic equilibrium between the rate of assembly and disassembly 
establishes the directionality and growth of neurites (Benitez-King et al., 2004). Whenever 
necessary, this process of polymerization-depolymerization together with microtubular 
nucleation can be controlled with the help of microtubule-binding proteins (Fig. 1.5) (Benitez-King 
et al., 2004; Mandelkow and Mandelkow, 1995). Furthermore, they facilitate the formation of 
higher order microtubular structures such as axonemes, centrioles and axonal bundle formation 






Fig. 1.5 Microtubules: from monomers to complex structures 
- and -tubulin monomers form heterodimer complexes, which further grow into protofilaments. The 
protofilaments assemble into hollow cylinders known as microtubules (MTs). The MTs are polar structures, 
which then can assemble into complex cytoskeletal formations such as axonal bundles with the help of 
microtubular associated proteins  (MAPs), depicted as brightly colored structures .  
1.4.1. The MAP1B family 
Microtubule associated proteins (MAPs) bind to microtubules and stabilize them (Fig. 1.5) 
(Mandelkow and Mandelkow, 1995). MAP1B is one of the earliest expressed MAPs in the brain 
and its expression drops drastically towards the end of neurogenesis (Tucker et al., 1989). This 
drop in expression is then matched by an increase of expression of the MAP1A complex (Binder et 
al., 1984).  While MAP1A and MAP1B are predominantly expressed in neurons, MAP1S is the only 
member of the MAP1 family that is ubiquitously expressed in almost all tissues (Orban-Nemeth et 
al., 2005).  The expression of MAP1B is highly regulated so that it coincides with the commence of 





neuritogenesis (Bloom et al., 1985; Riederer et al., 1986). The knockout of Map1b in mice leads to 
the complete absence of the corpus callosum, additionally establishing MAP1B as a major factor 
in axonal outgrowth during synaptogenesis (Meixner et al., 2000).  
The MAP1B transcript encodes a polyprotein that is post-translationally cleaved into heavy 
chain (HC) and light chain, known as LC1 (Hammarback et al., 1991). The HC and the LC then 
associate back together in a non-covalently bound manner and in a stoichiometric ratio of 1:2 
respectively to form the MAP1B protein (Hammarback et al., 1991). MAP1B LC1 is thought to 
mediate the interaction between the HC and MTs, since it contains MT binding domain (Togel et 
al., 1998a). Further analysis revealed that MAP1B LC1 is the active subunit, required for 
microtubular stabilization, where the HC most likely acts as regulatory particle by reducing the 
LC1’s binding capacity to MTs (Diaz-Nido et al., 1990; Togel et al., 1998b). Intriguingly, MAP1B is 
highly phosophorylated protein, and the binding affinity to MT is regulated by the degree of 
phosphorylation, suggesting that this type of post-translational modification may inflict 
conformational change in the MAP1B complex, liberating the LC1 and thus allowing it to stabilize 
MTs (Diaz-Nido et al., 1990; Togel et al., 1998b). Functionally, MAP1B LC1 induces tubulin 
polymerization and because of its expression in early development, it plays an important role in 
axonal growth and elongation, where knocking-out of the Map1B resulted in shorter axons in 
cultured neurons (Gonzalez-Billault et al., 2001; Gonzalez-Billault et al., 2002; Noiges et al., 2002).  
1.4.2. The role of MAP1B LC1 in microtubular transport  
Another important function of microtubules is to provide a structural track for organellar 
transport (Mandelkow and Mandelkow, 1995). As previously noted, MTs are polarized structures, 
and in axons, there is very strict directionality, where the minus end is facing the soma, and the 
positive end faces the synapse (Baas and Black, 1990). A second type of MAPs facilitate the 
transport of organelles along the axon, depending on cellular demand (Mandelkow and 
Mandelkow, 1995). Kinesins are responsible for plus-end transport, and dyneins traffic organelles 
towards the minus-end (Mandelkow and Mandelkow, 1995; Schnapp and Reese, 1989; Schnapp 
et al., 1992). Although the MAP1B has a distinct function in axonal growth by regulating MT 
dynamics, it was also recently found to limit retrograde transport of mitochondria along the axon 
when overexpressed (Jimenez-Mateos et al., 2006). This implicates that overstabilization and 
overabundance of MAP1B can in turn cause blockage of binding sites for motor proteins, reducing 
the capacity of cells to shuttle cargo from the synaptic termini back to the soma (Jimenez-Mateos 





1.4.3. The Mitochondria-UPS relationship in neurodegenerative disorders 
Mitochondria are the power plants of the cell. Just like fossil -fueled reactors, they convert 
energy stored in the strong covalent bonds in organic molecules into electric potential  (Brookes et 
al., 2004). This process is termed oxidative phosphorylation because the potential is then further 
utilized for the phosphorylation of adenosine diphosphate (ADP) into ATP at the expense of 
oxidizing nutrients (Brookes et al., 2004). This process requires a series of reduction and oxidation 
reactions, where the final outcome is reducing oxygen into water (Brookes et al., 2004). The 
fundamental need and benefits of producing energy, however does not come without costs: 
oxidative phosphorylation generates highly reactive oxygen radicals such as peroxide and 
superoxide, commonly referred as reactive oxygen species (ROS)  (Sena and Chandel, 2012). Cells 
and mitochondria are equipped with a battery of mechanisms to fend off ROS and to try and 
repair or degrade proteins, DNA or lipids that have been damaged by ROS as discussed in Section 
1.3.3. If one of these lines of defense fails due to genetic or environmental reasons, the balance of 
the system is thrown off, ultimately leading to cellular collapse (Fig. 1.6). The disruptive 
relationship between mitochondria and the UPS can be reciprocal: aberrations in mitochondria 
lead not only to a decrease in ATP production necessary for the UPS to function, but also to 
increase in the number of damaged and misfolded proteins, overwhelming the UPS (Fig. 1.6) 
(Nakamura and Lipton, 2009). Conversely, pathological protein accumulations causing UPS strain 
or intrinsic aberrations in the UPS can lead to failure in maintaining healthy mitochondrial 
proteostasis followed by mitochondrial dismay and triggering an increase in ROS production (Fig. 
1.6) (Branco et al., 2010). These two processes then enter a cycle of fueling each other’s 
detrimental effects (Fig. 1.6).  
Neurons are particularly sensitive to oxidative stress because of the high-energy demands 
required for the action potential propagation and the maintenance of the resting membrane 
potential (Chang and Reynolds, 2006). Furthermore, the “power plants” are  frequently located at 
the synapse- the most energy-demanding and Ca2+ rich location, since cellular calcium levels are 
buffered by mitochondria (Chang et al., 2006a; Friedman and Nunnari, 2014; Morris and 
Hollenbeck, 1993). Aberrant mitochondria located at the synapse and are destined for repair need 
to be transported back to the soma, in order to fuse with the lysosomes (Friedman and Nunnari, 
2014). Blocking the retrograde axonal transport can lead to aggregation of damaged mitochondria 
leading to the domino effect of the dysfunctional mitochondria-UPS relationship (Fig. 1.6) 







Fig. 1.6  Neuropathological relationship between mitochondria and the UPS 
Aberrant mitochondria lead to decreased adenosine triphosphate (ATP) production accompanied by the 
increase in the reactive oxygen species (ROS) generation and protein, DNA and lipid damage. This in turn 
may stress the ubiquitin proteasome system (UPS), reducing its capability to degrade damaged proteins, 
causing protein aggregations and accumulation. Failure in the UPS to clear out misfolded and damaged 
mitochondrial proteins results in mitochondrial dysfunction, closi ng off the cycle. The perpetuation of these 
processes can eventually lead to cellular death. 
1.5. Aim of the study 
In this study, I applied different biochemical and genetic techniques to examine the role of the 
parkinsonism-associated protein FBXO7 in cells in culture as well as neurons in vivo. FBXO7 is 
involved in multiple pathways, and in my investigation of the functional analysis of FBXO7, I 
focused on how loss-of-function of Fbxo7 affects mitochondrial health and neuronal morphology. 
I also evaluated the consequences of knocking-out Fbxo7 in the forebrain, and saw a generalized 
response following brain damage, highlighting the importance of FBXO7 in neuronal health.  
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2. Materials and Methods 
2.1. Materials 
2.1.1. Laboratory Equipment 
The experiments were carried out using the following Laboratory Equipment: 
micropipettes: Gilson, USA; consumables and plastic ware: Eppendorf, Hamburg, Germany; 
Thermo Fisher Scientific, Waltham, USA; Sarstedt AG & Co,  Germany; Falcon BD, Le Pont de Claix, 
France; Greiner Bio-One, Frickenhausen, Germany; Croning|Sigma Aldrich, Munich, Germany; 
Tabletop Centrifuges: Eppendorf, Hamburg, Germany/ Thermoscientific, Waltham, USA; Heating 
blocks: Grant Instruments, UK; Thermoshaker: Biometra, Jena, Germany; Rocker and Shaker: 
Heidolph, Germany; Spectrophotometer: Amersham Biosciences, UK/ TECAN Infinite M200, 
Männedorf, Switzerland; UV Transilluminator: Intas, Germany; Chemiluminescence 
Documentation System Alliance: Biometra, Jena, Germany; Thermocycler: Biometra, Jena, 
Germany; Dissection Microscope: SMZ645, Nikon, Japan;  Brightfield Light Microscope: Zeiss 
Axiophot, Oberkochen, Germany; Fluorescent Microscopes: Eclipse TI, Nikon, Japan/ Olympus 
BX51, Japan; Inverted Light Microscope: Eclipse TS100 Nikon, Japan/ Olympus CKX 41, Japan; 
Embedding Tissue Processor: HMP 110, MICROM; Microtome: HM 430, Thermo Fisher Scientific; 
Waterheating basin: HIR-3, Kunz Instruments. 
2.1.2.  Reagents, Chemicals and Kits 
All the reagents and chemicals used in this study (unless otherwise indicated) were 
purchased from Applichem (Darmstadt, Germany), Biomol (Hamburg, Germany), Bio-Rad 
Laboratories (Hercules, USA), DAKO North America, Inc. (Carpinteria, USA), GE Health Care (New 
Jersey, USA), Invitrogen (Darmstadt, Germany), Merk (Darmstadt, Germany), New England 
BioLabs (Frankfurt, Germany), Promega (Fitchburg, USA), Roth (Karlsruhe, Germany), Sigma- 
Aldrich (Munich, Germany), Thermo Fisher Scientific (Massachusetts, USA) and Worthington 
(Lakewood, USA).  
All media and supplements for used for primary and immortalized cell culture were 
purchased from GIBCO|Thermo Fisher Scientific (Massachusetts, USA). 
The Commercially available kits used for DNA extraction and purification - Nucleobond Xtra 
Midi EF, NucleoSpin Plasmid QuickPure and Nucleospin Gel and PCR Clean-up kit were purchased 
from Macherey-Nagel (Düren, Germany). 
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DNA and Protein ladders were supplied by Fermentas|Thermo Fisher Scientific 
(Massachusetts, USA). 
Mounting solution for immunohistochemistry was obtained from Eukitt (Freiburg, 
Germany). The paraffin used for embedding the brain tissue was produced by Paraplast, Leica 
(Wetzlar, Germany). 
2.1.3. Antibodies 
List of the primary and secondary Antibodies used in this study is summarized in Table 2.1 
and Table 2.2: 
Table 2.1  Primary Antibodies used and their specifications 
Primary 
Antibody 
Application Dilution Host Source Type 
14-3-3 WB 1:5000 mouse Santa Cruz monoclonal 
-synuclein IHC 1:200 rabbit Invitrogen monoclonal 
-galactosidase ICC 1:1000 mouse Santa Cruz monoclonal 






















HA WB 1:500 mouse Santa Cruz monoclonal 
GFAP IHC 1:200 mouse Nova Castra monoclonal 
Iba1 IHC 1:1000 mouse WAKO monoclonal 




mouse Santa Cruz monoclonal 
NFM IHC 1:500 mouse Santa Cruz monoclonal 
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cullin1 WB 1:50 mouse Santa Cruz monoclonal 
FBXO7 WB 1:500 mouse Santa Cruz monoclonal 
MAP2 ICC 1:1000 mouse Santa Cruz monoclonal 
 
Table 2.2  Secondary Antibodies used in this study 
Secondary 
Antibody 
Conjugated probe Application Dilution Host Supplier 
-mouse IgG HRP WB 1:10000 goat Dianova 
-mouse IgG Cy2 ICC 1:1000 goat Dianova 
-rabbit IgG Cy2 ICC 1:1000 goat Dianova 
-mouse IgG Cy3 ICC 1:1000 goat Dianova 
-rabbit IgG Cy3 ICC 1:1000 goat Dianova 
 
2.1.4.  Enzymes 
All enzymes used in this study are listed in Table 2.3 
Table 2.3  List of Enzymes used 
Enzyme Supplier 
Restriction Enzymes New England Biolabs 
GoTaq DNA Polymerase Promega 
Pfu DNA polymerase Thermo Fisher Scientific 
T4 DNA Ligase Thermo Fisher Scientific 
Proteinase K AppliChem 
DNase I Roche 
Alkaline Calf Intestinal Phosphatase New England Biolabs 
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2.1.5. Solutions, Media and Buffers 
The solutions, media and buffers used in this study are listed in Table 2.4. 
Table 2.4  List and recipes for all buffers and solutions used in this study 




















Enriched DMEM for 
HEK 293T cells 
DMEM [+] 4.5 g/L glucose, [-] glutamine, [-] pyruvate, 10% 




45% DMEM [+] 4.5 g/L glucose, [-] glutamine, [-] pyruvate, 
45% F12 Nutrient Mixture [+] GlutaMAX, 10% heat 
inactivated calf serum (HyClone) 
7.4 













s 2XHBSS 50 mM HEPES, 280 mM NaCl, 10 mM KCl, 15 mM glucose, 
1.5 mM Na2HPO4 
7.05-
7.11 






















HHGN 1X HBSS (from 10X stock Gibco), 2.5 mM HEPES, 35 mM 
glucose, 4 mM NaHCO3 
7.4 
TDn 50 mg Trypsin (Worthington), 250 L DNase (stock 2 
g/L), 5mL HHGN 
7.4 








Triton X-100 lysis 
buffer 
150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 1% Triton X-
100 
7.4 
Co-IP buffer 150 mM NaCl, 20 mM Tris-HCl, 1 mM EDTA, 1% Nonidet P-
40, 10% Glycerol 
7.4 
RIPA Buffer 150 mM NaCl, 5 mM Tris-HCl, 1 mM EDTA, 1% Nonidet P-
40, 0.5% sodium deoxycolate, 0.1 % SDS 
- 
Ubiquitination 
Assay Lysis Buffer 
150 mM NaCl, 50 mM HEPES, 1.5 mM MgCl2, 1% Triton 
X-100, 10% Glycerol 
- 
4X SDS Sample 
buffer 
300 mM Tris- HCl pH 6.8, 10 % SDS, 50% Glycerol, 25% - 
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Lower Buffer 1.5 M Tris- HCl, 0.4% SDS 8.8 
Upper Buffer 0.5 M Tris- HCl, 0.4% SDS 6.8 
Running Buffer 125 mM Tris, 1.25 M glycine, 0.5% SDS - 
Transfer Buffer 20 mM Tris, 153 mM glycine, 20% Methanol - 



























10% Ketamine v/v (10% Medistar, Arzneimittelvertrieb 














0.2 M Phosphate 
Fixation Buffer 
0.36% w/v NaH2PO4, 3.1% w/v Na2HPO4, 1% w/v NaCl ~7.4 
4% PFA for paraffin 
embedding 
4% w/v PFA, 0.1 M phosphate fixation buffer - 
Citrate Buffer 1.8 mM C6H8O7H2O, 8.2 mM C6H5Na3O72H20 6.0 
Tris Buffer 0.9% w/v NaCl, 50 mM Tris-Cl 7.6 





10 mM Tris- HCl, 100 mM NaCl, 0.1% NP40 7.4 
Blocking Buffer 20% Goat Serum v/v in BSA/PBS - 
Scott's reagent ready to use - 
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Table 2.4  List and recipes for all buffers and solutions used in this study (Continued) 
 
Haematoxylin ready to use - 












8% PFA 40 g PFA, 50 mL 10X PBS, 40 g Sucrose in final volume of 





0.4% Tx-100 v/v in PBS 7.4 
BME Blocking Buffer 10% heat inactivated Goat/Horse serum in BME [+] Earle's 
salts [-] L-glutamine 
- 
DAPI 1 g/L stock, dilution 1:8000 in ddH2O - 
Mowiol Mounting 
Media 
6 g 85% Glycerol, 2.4 g Mowiol 4-88, 6 mL H2O, 12 mL Tris-
























Annealing Buffer 1 M Tris- HCl, 2 M KCl 7.5 
2X TAE 80 mM Tris-Acetate, 2 mM EDTA 8.5 
2X YT medium 5 g NaCl, 16 g tryptone, 10 g yeast extract in 1 L ddH2O - 
2X YT agar plates 1.5% agar, 50 g/mL Ampicillin/Kanamycin - 
LB broth 20 g LB in 1 L sterile H2O - 
LB agar plates 32 mg LB agar in 1 L sterile H2O - 
 
2.2. Methods 
2.2.1. Molecular cloning  
i. Molecular cloning of the MAP1S LC expression plasmids  
Cloning of the MAP1S LC cDNA in pCMV10-3xFLAG expression vector, required primers, 
designed to target the gene of interest and be unique for that sequence. The primers chosen have 
the following nucleotide sequence: 
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           Forward primer: 5'- ATAAAGCTTATGGTGGACCCGGAGGCGCTA - 3' 
           Reverse primer:  5'- CTCGTCGACCTAGAACTCCACCTTGCAGGCC - 3' 
 
Since each primer has a unique melting temperature (Tm), they were also so designed as to have 
similar Tm, which then served as guidelines for the annealing temperature for the primers, set to 
be 5C below the Tm. The elongation step was also estimated, taking under consideration the 
elongation rate of the Pfu polymerase of 500bp/min. The reagent mixture settings are mentioned 
in Table 2.5: 
Table 2.5  Reagent mixture settings 
Reagent Volume (L) 
Template DNA (50 ng) 0.5-1 
Forward and reverse primers (10 pmol/L) 1 
dNTP (25 mM) 0.4 
Pfu DNA Polymerase 0.5 
10x Pfu polymerase reaction buffer  5 
Total reaction Volume 50 
 
This reaction mixture was then subjected to amplification by a polymerase chain reaction 
(PCR) following the protocol form Saiki et al., with modifications to achieve exponential 
multiplication of the desired product (Saiki et al., 1985). The PCR settings for molecular cloning of 
the MAP1S LC were set as in Table 2.6: 
Table 2.6  PCR settings for molecular cloning of the MAPS1S LC 
Process Temperature (C) Duration (min) 
Initial denaturation 95 3 
PCR denaturation 95 0.5 
30 cycles Primer annealing 57 0.5 
Elongation 72 2 
Final elongation 72 10 
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The resulting PCR product was then ran through 1% agarose gel electrophoresis and the 
bands corresponding to the correct insert size were excised and purified using Nucleospin Gel and 
PCR Clean-up kit following manufacturer’s instructions.  The PCR product was then eluted in 60 L 
ddH2O and digested for 2 hours and 37C using 2 L of the HindIII and SalI restriction enzymes 
(final reaction volume 60 L) corresponding to the cutting sites on the designed primers and the 
vector's multiple cloning site. 3 g of the pCMV10-3xFLAG vector was also digested and then 
dephosphorylated using CIP for 1 hour at 37C. Next, both the vector and the insert from the 
digestion reactions were purified and eluted using Nucleospin Gel and PCR Clean-up kit 
(Macherey-Nagel) according to manufacturer’s instructions in 15 L and 50 L ddH2O 
respectively. 
The purified products were used to set up a ligation reaction as listed in Table 2.7: 
Table 2.7  Ligation reaction settings 
Reagent Volume (L) 
Dephosphorylated pCMV10 vector 1 
Insert  3.5 
ATP (10 mM) 0.6 
10x T4 ligation buffer 0.9 
T4 DNA ligase 1 
Final volume 10 
 
    The ligation reaction was left overnight in icy water, to gradually increase the temperature to 
RT. 
ii. Bacterial transformation, inoculation and plasmid verification 
The ligation reaction was used to transform DH5 E. coli bacteria by incubating the whole 
reaction mixture with 10 L of the highly competent bacteria for 30 min on ice. Next, the bacteria 
were heat- shocked for 2 min at 37C, placed back on ice. 300 L of the 2x YT medium was added 
to the tube, and the cells were allowed to grow for 30 min at 37C.  The cells were then spun 
down at 4000 rpm for 3 min, approximately 300 L of the supernatant was removed and the cells 
were resuspended in the remaining supernatant and plated onto ampicillin agar plate. 
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Colonies were picked and inoculated in 2 mL of the 2x YT medium containing ampicillin 
(1:1000) overnight. The DNA was extracted using the NucleoSpin Plasmid QuickPure (Macherey-
Nagel), and the purified DNA from 10 colonies was tested for the presence of the insert through 
restriction test digest. To finalize the cloning process, samples from positive clones were sent for 
sequencing by the AGTC Lab at the Max Planck Institute of Experimental Medicine, Göttingen. 
iii. Molecular cloning of vector-based RNA interference oligonucleotides 
The MAP1B LC1 shRNAs were designed to target the protein expression in human, mouse 
and rat. The sense shRNA sequence was homologous to a targeted mRNA region (highlighted in 
red) on the MAP1B LC1, followed by a 9-nucleotide loop and then the antisense sequence: 
5'-GGCCTCCCTGTGTATTTGGAAAGTTAACGTCCAAATACACAGGGAGGCC -3' 
For the annealing of the primers, 2 L of each oligonucleotide (50 pmol/L) were incubated 
first for 5 min at 95C, then 10 min at 72C in 46 L annealing buffer, and then the reaction 
mixture was allowed to cool down at rate of 0.1C/sec. Next 20 L of the annealed 
oligonucleotides were phosphorylated for 30 min at 37C using reaction mixture in Table 2.8: 
Table 2.8  Reaction mixture for annealing of the primers 
Reagent Volume (L) 
Annealed oligonucleotides 20 
10x PNK buffer 5 
PNK 1 
ATP (10 mM) 0.5 
Final volume 50 
 
Next, 4 L of the phosphorylated oligonucleotides were ligated with 1L of the pre-
digested (Bgl II and Hind III) and pre-dephosphorylated pSuper vector as described previously in 
Section 2.2.1.i. Next, the ligation reaction was used to transform SURE bacteria following the 
DH5 bacterial transformation protocol (Section 2.2.1.ii), except the volume of bacteria used was 
100 L. The bacteria were plated and subsequently inoculated as described earlier, and a test 
digest using HpaI (specifically cutting through the 9 bp loop sequence) was used to identify the 
positive clones. 
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2.2.2. Immortalized cell lines maintenance and transfection 
All cell cultures were maintained in HERAsafe or alternatively HERAcell 150i (Thermo 
Fisher Scientific) under sterile conditions at 37C and 5% CO2. Propagation, maintenance and 
transfection of all cell lines were carried out under a sterile biological safety hood HERAsafe 
(Thermo Fisher Scientific). 
i. HEK 293T cells passaging: 
HEK 293T cells were grown in enriched DMEM at 37C and 5% CO2. At about 100% 
confluency, the HEK 293T cells were regularly passaged by washing them with 4-5 mL sterile PBS 
and then trypsinizing them with 2 mL trypsin-EDTA for no longer than 2 minutes at 37C. 
Trypsinization was stopped using 8 mL enriched DMEM and the detached cells were collected in a 
15 mL FALCON tube and spun at 4C for 5 min at 800 rpm. The medium was aspirated and the cell 
pellet was carefully resuspended in 9 mL of fresh enriched DMEM. The cells were the n seeded in 
10 cm cell culture dishes in dilution 1:10 for further passaging. For biochemical experimental 
procedures, 200 L of the cell resuspension was seeded in 2 mL enriched DMEM in 6-well plates 
or alternatively, 20 L of the cell resuspension was seeded onto poly-ornithine coated glass slides 
in 500 L enriched DMEM in a 24-cell plate. 
ii. HEK 293T cell transfection: 
Once reaching confluency of 60-80%, the HEK 293T cells were transfected following a 
modified version of the Calcium Phosphate Transfection protocol (Konishi et al., 2004). Briefly, 90 
L of ddH20 containing the desired amount of plasmid was mixed with10 L 2.5 M CaCl2. To this 
solution, 100 L 2xHBSS (pH 7.08-7.11) was pipetted in by introducing bubbles during the mixing. 
The DNA was allowed to precipitate for 5 minutes at RT, and the final volume of 200 L was 
added dropwise to the cells in the 6-well plate.  
HEK 293T cells seeded in 24-well plates were transfected using the same method, but with 
final volume of DNA in ddH2O of 20 L, mixed with 2 L 2.5 M CaCl2 and 20 L 2xHBSS (pH 7.08-
7.11).  
iii. SH-SY5Y cells passaging: 
The SH-SY5Y cells were grown and maintained in Enriched DMEM/F12 medium at 37oC and 
5% CO2. The medium was regularly exchanged every 3-4 days. The cells were passaged after 
reaching confluence of about 80% by washing them with sterile PBS followed by trypsinization for 
no more than 1 min. The cells were then collected in 8 mL DMEM/F12 medium and spun down for 
3 min at 300 rpm and 4oC. The supernatant was discarded and the SH-SY5Y cells were then 
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resuspended in 5 mL DMEM/F12. The cell count was determined using haemocytometer and the 
cells were seeded as needed in 24-well plates (60 000- 100 000 cells) onto 12 mm coverslips, 
previously incubated for minimum 30 min at 37 oC with poly-ornithine and then washed with 
ddH2O. 
iv. SH-SY5Y transfection: 
The SH-SY5Y cells were transfected using Lipofectamine 2000 following the manufacturer 
instructions and adapting them for maximal efficacy. Briefly, 2 L of Lipofectamine diluted in 50 
L GIBCO Opti-MEM (Thermo Fisher Scientific) was carefully mixed with 50 L GIBCO Opti-
MEM containing the required plasmid dilute. The lipofectamine and DNA mixture was then 
incubated for 10 min, to ensure DNA entrapment into the lipid droplets, and then it was added 
dropwise to the cells. The medium was exchanged within 6-18 hours with warm DMEM/F12. 
2.2.3. Primary cortical cell culture generation, maintenance and transfection 
Primary cell cultures were maintained in HERAsafe or alternatively HERAcell 150i (Thermo 
Fisher Scientific) under sterile conditions at 37C and 5% CO2.  Generation, maintenance and 
transfection were carried out under a sterile biological safety hood HERAsafe (Thermo Fisher 
Scientific). 
i. Primary cortical culture generation 
P0-P2 C57BL/6N pups were decapitated and the brains were isolated in cold 1xHBSS 
medium. The cortices were dissected out, ensuring that the meninges, the midbrain, 
hippocampus, and olfactory bulbs were removed. All of the following steps were performed in 
sterile conditions. The cortices were washed three times in cold 1xHBSS, and the neurons were 
dissociated in TDn for 10-15 min at 37oC and 5% CO2. Washing the cortices again with 1xHBSS 
terminated the trypsin digestion. To completely dissociate the neurons, a 10 mL serological 
pipette was used to triturate the cells in 5 mL plating medium containing freshly added DNase (2 
mg/mL).  The cell suspension was then centrifuged at 800 rpm for 7.5 min at 4oC. Next, the 
supernatant containing cellular debris was aspirated off, and the remaining pellet was once more 
resuspended in 10 mL of cold plating medium. The cells were counted and plated at desired 
density (0.75-1.2 x106) in a final volume of 500 L onto 12 mm poly-ornithine coated cover slips in 
24-well plates. Neuronal cultures kept for longer than DIV6, were supplied with 15 L 1M glucose. 
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ii. Primary cortical culture transfection 
The cortical neurons were transfected using calcium chloride at either DIV1 for axonal 
length analysis or at DIV3 for all other experiments. The conditioned plating medium was 
collected and the cells were washed three times with warm DMEM ([+] 4.5 g/L glucose, [ -] 
glutamine, [-] pyruvate). The cells were then left to starve in glucose free 0.5 mL DMEM at 37oC 
and 5% CO2 for 45-60 min. Meanwhile, the required DNA concentration was diluted in ddH2O for a 
final volume of 18 L. 2 L CaCl2 was then pipetted into the mixture, and finally 20 L 2xHBSS of 
optimal pH (7.08-7.11) was added, by introducing bubbles. The final solution was incubated for 8 
min at RT, and was then added drop-wise to the neuronal culture and incubated for 18 min at 
37oC and 5% CO2. Finally, the DNA/CaCl2 mixture was washed away thoroughly with DMEM ([+] 
4.5 g/L glucose, [-] glutamine, [-] pyruvate) and the neurons were allowed to incubate further in 
the original plating medium.  
2.2.4. Immunocytochemistry 
Cells were fixed by washing them twice with PBS and then incubating them in 4% PFA in 
PBS for 10 minutes. The PFA was washed 2-3 times using PBS and then the cellular membranes 
were permeabilized with 0.4% Triton X-100 in PBS [v/v] for 10 min at RT and then washed again 
with PBS. The cells were then blocked for minimum of 30 min at RT with 10% horse serum (HS) in 
BME, and the cover slips were transferred onto a wet, light-impermeable chamber. Next, 50 L of 
the primary antibody diluted in 10% HS in BME was added to the sides and incubated according to 
the optimized results. The primary antibody was washed using the HS in BME. Secondary antibody 
also diluted in 50 L HS in BME was incubated for 45-60 min and washed with PBS. Optionally, the 
cellular nuclei were stained with DAPI for 8 min at RT, and washed with PBS. Lastly, the cover slips 
were mounted onto microscope slides (Marienfeld, Germany) using Mowiol. 
2.2.5. Axonal and total dendritic length analysis 
The cultured neurons were transfected at DIV 1 as described in Section 2.2.3.ii with the 
plasmid of interest together with c1-GFP plasmid serving as transfection marker and the anti-
apoptosis protein Bcl-xL. Immunocytochemistry was performed at DIV6, and the transfected 
neurons were visualized under an epifluorescent microscope (Eclipse TI, Nikon). Next, 40-60 
transfected neurons per condition with healthy nuclei were imaged (NIS- Elements Basic 
Research, Nikon Instruments) and the axonal and the dendritic lengths were determined using the 
ImageJ macro plug NeuronJ (NIH). 
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2.2.6. Biochemical Methods 
i. Cell lysis 
The HEK 293T or the SH-SY5Y cells were washed with cold PBS to ensure the removal of any 
dead cells. Next, 200 L of cold Triton X-100 lysis buffer or co-immunoprecipitation buffer 
containing 3 g/mL Aprotinin, 1 g/L Leupeptin and 1 g/L Pepstatin protease inhibitors 
together with 1 mM 1,4-dithiothreitol (DTT) as reducing agent were pipetted into the 6-well 
plates. The cells were then scraped off the surface of the plates using cell scraper (Greiner Bio-
One|VWR), collected and incubated 30 min on ice. The lysates were then spun down at 14 000 
rpm for 10 min at 4oC. The supernatant was used for further analysis and the pellet was discarded. 
ii. Protein concentration determination 
Protein concentration was determined using the Bio-Rad Protein Assay based on the 
Bradford Method (Bradford, 1976). Briefly, the reagent was diluted 1:5 in cold PBS and 1 mL of 
the diluted reagent was pipetted into disposable spectrophotometer cuvettes (Greiner Bio-
One|VWR). 2 L of the lysate was pipetted into the cuvettes and the mixture was thoroughly 
vortexed to ensure even distribution of the proteins. Next, the absorbance at wavelength 595 nm 
was determined using spectrophotometer. Furthermore, a standard curve was generated by 
measuring the absorbances corresponding to 5, 10 and 15 g/ml BSA in the diluted Bradford 
reagent, and the resulting correlation curve was used to calculate the relative lysate 
concentration.   
Alternatively, the concentration was determined using a modified version of the Lowry 
Protein assay (Lowry et al., 1951). 24.5 L of Reagent A was mixed with 0.5 L of reagent S 
(DCProtein Assay, BioRad, USA). The mixed reagents were then pipetted into 96-well Nunclon 
Delta surface plate (NUNC|Thermo Fisher Scientific, Denmark). 5 L of 0.0, 0.2, 0.5, 0.8, 1.2 and 
1.2 g of BSA diluted in the same buffer as the samples (necessary for generation of the standard 
curve) as well as 5 L of the samples was pipetted into the Reagent A+S. Finally, 200 L of the 
Folin–Ciocalteu reagent was added and the reaction was allowed to develop over 15 min at 26oC 
with initial 5 seconds shaking. The absorbance at 750 nm was measured using the TECAN Infinite 
M200 and analyzed by the i-control 1.8 SPI software. 
iii. Co-immunoprecipitation 
After protein determination, 0.75-1.5 mg of protein was pipetted into a 1.5 mL tube and 
the final volume was equalized for all samples using co-immunoprecipitation buffer. 50 g of 
protein from the total cell lysate was boiled in 4xSDS Sample buffer for 5 min at 95oC to serve as 
 
2. Materials and Methods 
33 
 
input control. The optimized amount of primary antibody was added to the lysates and allowed to 
incubate rotating for 2-4 hours at 4oC according to on the antibody specifications. 15-20 L of 
Protein A Sepharose beads slurry (Protein A Sepharose Fast Flow, GE Healthcare, UK), 
previously washed with co-immunoprecipitation buffer with final dilution 1:1, were added to the 
lysates. After 1 hour incubation at 4oC on the roller mixer, the beads were collected at the bottom 
of the tube (10 000 rpm, 1 min at RT), and washed 2-3 times either with 200-300 L of the 
Triton X-100 lysis buffer or the RIPA buffer followed by 300 L PBS wash. Finally, approximately 
30 L of 4xSDS Sample buffer was pipetted and mixed into the beads followed by a 5 min 
denaturating step at 95oC.  
iv. Ubiquitination assay/ Interaction strength assay 
The cell-based ubiquitination assay was performed following a modified version of the 
methods described in Lu et al. (Lu et al., 2007).  The transfected HEK 293T cells were washed with 
cold PBS and lysed in 200 L RIPA (without SDS) supplemented freshly with 3 g/mL Aprotinin, 1 
g/L Leupeptin, 1 g/L Pepstatin as well as 10 mM N-ethylmaleimide (NEM) serving as a 
deubiquitinase inhibitor (addition of NEM was omitted for the mutant interaction strength 
analysis). Once the cellular debris was discarded and the protein concentration determined, 50 g 
of the lysate was denatured by boiling it with 4xSDS. 1 mg of protein per sample was then 
pipetted into a 2 mL Eppendorf tube, and the volumes of all samples were equalized using RIPA 
buffer. In order to avoid unspecific ubiquitin smears possibly resulting from autoubiquitination  of 
FBXO7, the samples were first incubated with 1.5 % SDS for 10 min on the roller mixer at RT, 
followed by boiling step at 95oC for 30 min. The samples were then transferred onto 15 mL test 
tubes and diluted 1:10 in Ubiquitination Assay Lysis bufer. The samples were then incubated with 
10 L anti-FLAG M2 affinity Gel beads (SIGMA ALDRICH) overnight on the roller mixer at 4oC. 
For the interaction strength assay, an initial incubation with 0.75 L anti-FLAG antibody for 1 hour 
at 4oC was followed by 1 hour incubation with 20 L Protein A Sepharose bead slurry. The beads 
were then transferred back into 1.5 mL tubes and washed twice with RIPA (with SDS) or 
alternatively for the mutant interaction strength assay- lysis buffer, followed by a PBS wash. 
Finally the proteins were eluted from the samples by boiling them for 5 min with ca. 30 L SDS 
Sample buffer. 
v. Quantitative mass spectrometry sample preparation 
The transfected HEK 293T cells were lysed in co-immunoprecipitation buffer as previously 
described in Section 2.2.6.i. 500-750 g dry protein weight was incubated with 20 L anti-FLAG 
M2 affinity Gel beads (SIGMA ALDRICH) for 4 hours at 4oC on the roller mixer. The beads were 
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spun down at 6000 rpm, and washed twice with lysis buffer and twice with cold PBS, resuspended 
in 20 L of PBS and snap frozen in liquid nitrogen and stored at -80oC. 20 g of the lysates were 
boiled with 4x SDS as input control as well  as 5 L of the immunoprecipitated solution. The mass 
spectrometry was performed by Dr. Christian Preisinger at the Proteomics Facility, 
Interdisciplinary Center for Clinical Research (IZKF) Aachen, Medical Faculty, RWTH Aachen. 
Briefly, the samples were digested using 2M urea, desalted and lyophylized. The peptides were 
resuspended in formic acid and analyzed using Orbitrap Elite mass spectrometer (Vingill et al., 
2016). The resulting data was analyzed using MaxQuant (v. 1.5.2.8) and SwissProt (v. 06/2015) 
Database (Cox and Mann, 2008; Cox et al., 2011; Vingill et al., 2016).  
vi. SDS-PAGE and Western Blotting 
The SDS-PAGE was performed following the method described in Laemmli et al.(Laemmli, 
1970), with modifications. The SDS-PAGE acrylamide gels were cast in the Mini-PROTEAN Tetra 
Electrophoresis System (BioRad) using the 1.0 or the 1.5 mm spacer plates and combs. Detailed 
volumes for the preparation of the gels are listed in Table 2.9: 
Table 2.9  Volumes of reagents used to prepare SDS-PAGE acrylamide gels 
 Separating Gel 
         10%                            12% 
Stacking Gel 
Acrylamide (mL) 2.5 3 0.65 
Lower/Upper Buffer (mL) 1.875 1.875 1.25 
H2O (mL) 3.125 2.625 3.05 
10% APS (L) 30 30 30 
TEMED (L)  3 3 3 
 
Firstly, the 10-12 % (depending on the experiment) separating gel was poured into the gel 
casting chambers and covered with 1 mL of isopropanol to ensure the removal of bubbles as well 
as sharp horizontal separation. Once the separating gel had solidified and the isopropanol 
washed, a 3.9 % separating gel was poured on top of the stacking gel, a comb was inserted and 
the stacking gel was allowed to polymerize.  
The denatured in 4xSDS sample Buffer lysates were loaded onto the gels together with 
PageRuler Prestained protein ladder (Thermo Fisher Scientific) and the proteins were resolved at 
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35 mA (max Voltage) per gel. After electrophoresis, the gels were stacked on top of a 
nitrocellulose blotting membrane (Amersham, GE Healthcare Life Sciences) and the proteins 
were transferred for 90-110 min at 250 mA using the wet transfer system Mini Trans-Blot 
(BioRad) or alternatively the dry transfer system from Biometra Analytic (Jena). The membranes 
were then incubated for 30 min, shaking at RT with 4% milk in PBST to block the potential sites of 
non-specific antibody bindings. Next, the membranes were washed 3 times each with PBST for 10 
min. The membranes were then incubated with the required primary antibody diluted in primary 
antibody blocking solution at the optimized dilutions and durations listed in Table 2.1. The 
membranes were then washed again three times with PBST and incubated for 35-45 min with 
secondary HRP-conjugated antibody diluted 1:10000 in 4% milk in PBST. After a final washing step 
with PBST, the membranes were incubated briefly with enhanced chemiluminescent horseradish 
peroxidase substrate kit (Pierce, ThermoFisher Scientific). The membrane was visualized either 
using a photographic film (Amersham Hyperfilm) that was developed in an automatic developer 
(Curix 60, Agfa) or using the Chemiluminescence Documentation System Alliance (Biometra) and 
the Alliance (UVITECH, Cambridge) software. 
2.2.7. NEX-Cre;Fbxo7fl/fl  mouse line generation and genotyping 
i. Generation of NEX-Cre;Fbxo7fl/fl transgenic mice  
The Fbxo7 knockout mouse line was generated as described in Vingill et al. by Nicola 
Schwedhelm-Domeyer, Cellular and Molecular Neurobiology, Max Planck Institute of 
Experimental Medicine, Göttingen (Vingill et al., 2016). In brief, embryonic stem cells containing 
the transgenomic sequence, where exon four of the Fbxo7 gene is flanked by loxP sites, were 
injected in pseudopregnant C57BL/6 mice to create chimeric offspring. The chimeric mice were 
then further bred until achieving homozygous offspring that was then crossed with a NEX-Cre 
mouse line to generate the NEX-Cre/Fbxo7fl/fl mice (Goebbels et al., 2006; Vingill et al., 2016)  
ii. Isolation of genomic DNA 
Genomic DNA for sequencing was extracted from the mouse tails, that were digested for 
minimum 2 hours in 200 L of Tail lysis buffer containing 3 L proteinase K (200 g/mL) and 8 L 
of 5 M NaCl. After ensuring that the tails are completely digested, the samples were spun down 
for 10 min at 14000 rpm and the supernatant was transferred into fresh eppendorf, omitting the 
undigested remains. The DNA was precipitated using 300 L of 99% ethanol and collected at the 
bottom of the tube by centrifugation for 3 min at max speed. The DNA was washed with 70% 
ethanol, air-dried, and finally resuspended in 100-200 L of ddH2O. 
 
2. Materials and Methods 
36 
 
iii. Genotyping  
Two separate primer sets were designed to genotype the NEX-Cre/Fbxo7fl/fl mice. The first 
set targets only Fbxo7 wild type alleles, where the second set would test for the expression of Cre 
recombinase. The list of the sequences of the primers used can be found in Appendix, Table  A. 
The primers were added to the genotyping mix as follows: 
Table 2.10  Genotyping reaction mix 
Reagent Volume (L) 
Genomic DNA 0.5-1 
Forward and reverse primers (10 pmol/L) 1 
dNTP (2.5 mM) 0.4 
GoTaq DNA Polymerase 0.1 
5x GoTaq reaction buffer 5 
Total reaction Volume 25 
 
The PCR reaction was then amplified using the programs that are mentioned in Table 2.11: 
Table 2.11  PCR thermocycler program used 
Process Temperature (oC) Duration (min) 
Denaturation 95 3 
PCR denaturation 95 0.5 
28 cycles Primer annealing 51 0.5 
Elongation 72 2 
Final elongation 72 10 
 
2. Materials and Methods 
37 
 
2.2.8. Immunohistochemistry  
i. Transcardial perfusion and fixation of mouse brains  
Adult mice were initially anesthetized by intraperitoneal injection of 10% ketamine [v/v] 
mixed with 5% xylazine [v/v]. The mice were fixed dorsally and their diaphragm was exposed and 
cut, allowing access to the heart. A butterfly cannula (Venoflix, Braun) connected to peristaltic 
pump was inserted carefully into the left ventricle avoiding piercing through the ventral wall of 
the heart or the left atrium. The right atrium was incised and PBS was allowed to flow through the 
peristaltic pump to flush away the blood form the organs. Next, freshly prepared 4% PFA for 
paraffin embedding was run through the pumps until the organs were fixed. The brain was 
dissected out and left overnight in 4% PFA at 4oC, and then diluted down to 1% PFA using PBS and 
left for another 2 days. 
ii. Post-fixation paraffin embedding and sectioning 
The fixed brains were embedded in paraffin (Paraplast, Leica) using a pre-set program of 
the embedding tissue processor described in Table 2.12: 
Table 2.12  Pre-set dehydration/paraffinization program  
Procedure Duration (hr) 
50% Ethanol 1 
70% Ethanol 2x2 
96% Ethanol 2x2 





Finally, the brains were positioned horizontally in metal moulds, embedded in 60oC paraffin 
and allowed to set by cooling. The paraffin blocks were cut into 5 m thin sections using a 
microtome, and then allowed to settle and unwrinkle in a 40oC water bath, collected onto slides 
and allowed to dry at RT. Dr. Siv Vingill kindly provided some of the brain samples. 
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iii. Deparaffinization, rehydration and antigen retrieval 
The sections were subjected to deparaffinization through two incubation steps with xylol, 
10 min each, and incubation with Xylol/Isopropanol (1:1) for another 10 min. The slides were then 
rehydrated in a series of 5 min incubation steps in decreasing percentages of ethanol (100%, 90%, 
70%, and 50%) and a final step of incubation in ddH2O. In order to ensure antibody-antigen 
binding, an antigen retrieval step was carried out by initially incubating the slides for 5 min in cold 
citrate buffer and then submerging the slides in preheated citrate buffer and a final boiling step at 
650 Watts for 10 min. The slides were then allowed to cool down at RT in the citrate buffer. 
iv. Immunohistological staining of tissues embedded in paraffin  
Proteinase K digestion step was preformed only for immunohistological staining with -
synuclein. The slides were incubated for 35 min at 37oC in 1:500 Proteinase K (200 g/mL) diluted 
in Proteinase K digestion buffer. The sections were rinsed with fine- filtered 2% milk in Tris buffer 
[w/v] and mounted into a vertical position with the help of cover plates (Shandon, Thermo 
Fisher Scientific, UK) and immunohistological rack. Special care was taken to avoid any trapped 
bubbles between the surface of the microscopy slides and the cover plates. The sections were 
washed in 2% milk in Tris buffer again, followed by endogenous peroxidase inhibition step 
performed by 5 min incubation with 3% H2O2. After one more wash with 2% milk in Tris buffer, 
the non-specific epitopes were blocked in blocking buffer for 10 min at RT and the primary 
antibody diluted in blocking buffer was incubated overnight at 4oC. On the next day, the slides 
were rinsed with 2% milk in Tris buffer and a secondary antibody conjugated to biotin (LSAB2 kit, 
Dako, USA) was incubated with the brain sections for 10 min at RT. Next, the slides were further 
incubated with peroxidase-conjugated streptavidin for 10 min, and finally rinsed with Tris buffer. 
The cover plates were then carefully detached from the coverslips, the sections of interest  were 
encircled using a Dako pen, and the binding sites were stained using the chromogen 3-3'-
diaminobenzidine (DAB) (Dako, USA) that results in brown precipitation in the presence of 
peroxidase activity. Finally, the slides were rinsed twice with ddH2O 
v. Nuclear staining, rehydration and mounting 
The sections were briefly dipped in 0.1% haematoxylin [w/v], rinsed in ddH2O and 
developed in HCl/Alcohol. To increase the saturation of the blue tint, the slides were dipped in 
Scott's solution (Thermo Fisher Scientific) and then rinsed once more with ddH2O.  Next, the slides 
were dehydrated using the same ethanol concentrations described in the previous section, but in 
the reverse order followed by Xylol/Isopropanol and two times 10 min Xylol incubation. Eukitt 
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(Kindler) mounting medium was spread thinly over cover slips, which were then carefully placed 
onto the slides, clearing off any air bubbles.  
vi. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay (TUNEL) 
assay 
The slides were deparaffinized and dehydrated as mentioned in Section 2.2.8.iii. The TUNEL 
assay was performed as per the manufacturer’s instructions- DeadEnd Colorimetric TUNEL 
System kit (Promega). Following heamatoxylin staining, the slides were rinsed in ddH2O and 
covered using the Aqua-PolyMount (Polysciences) mounting medium. 
vii. Imaging, analysis and quantification 
All images were acquired using a bright field microscope Axio-Observer Z1, Zeiss, and the 
ZEN 2011 imaging software. The number of cell nuclei stained by the TUNEL assay as well as the 
Iba1 positive cells were manually counted in blinded manner. The area quantification as well as 
the GFAP- and Iba1- positive areas was quantified using imageJ macro provided by Dr. Mitkovski , 
Max Planck Institute of Experimental Medicine, Göttingen, and previously published by Dr. David 







Although research in the FBXO7 field in the recent years has yielded results that are helpful 
in entangling the pathways of neurodegeneration, there are still many questions to be raised. 
Some of these questions were investigated in my research. For example, is FBXO7 localization 
nuclear or cytoplasmic? Does Fbxo7 knockout have effect on the cellular and/or mitochondrial 
morphology? Are there any unknown processes or interactors that FBXO7 may be involved 
in/with? And last but not least, what is the role of FBXO7 in the forebrain? To answer them, I used 
an array of biochemical, molecular, cellular and histological procedures, that resulted in the 
following findings: 
3.1. FBXO7 localization and interactome 
3.1.1. FBXO7 is localized in the cytoplasm 
Localization of FBXO7 in cells has been controversial. Previous immunocytochemical 
analysis on HEK 293T, SH-SY5Y cells and patients’ fibroblasts have showed that wild type FBXO7 
localizes to the nucleus (Zhao et al., 2011). However, in our laboratory, it was previously found by 
using the transgenic Fbxo7 knockout mice, that commercially available antibodies against FBXO7 
fail to detect the presence of FBXO7 by immunocytochemical analysis. Furthermore, nuclear 
fractionation assay results showed that FBXO7 was predominantly localized in the cytoplasmic 
fraction (Brockelt, 2015). In order to shed more light on the localization of FBXO7, I transfected 
different cell types with FBXO7 constructs that were tagged either C-terminally or N-terminally. 
Upon overexpression of the different FBXO7 proteins in mouse cortical neurons (Fig. 3.1 A), HEK 
293T (Fig. 3.1 B) and SH-SY5Y cells (Fig. 3.1 C), I saw that nearly all healthy cells had the FBXO7 

















Fig. 3.1  FBXO7 localizes to the cytoplasm 
 (A-C) Representative images of mouse cortical neurons (A), HEK 293T cells (B) or SH-SY54Y cells (C) 
transfected with tagged FBXO7 or control together with GFP transfection marker. The cells were 
transfected at DIV 3 and stained at DIV 8 (A) or at DIV 1 and stained at DIV 3 (B and C). The N-terminally 
Myc-tagged FBXO7 was then detected using the anti -Myc antibody as primary antibody and Cy3-conjugated 
secondary antibody, depicted in red. Cy2 was used to enhance the GFP signal depicted in green. The nuclei 
were counter-stained with DAPI. Magnification: 60x. Scale bar = 20 m.  
3.1.2. FBXO7 is involved in multiple cellular mechanisms according to quantitative 
mass spectrometry data 
There are several major interaction partners known for FBXO7 such as PINK1, Parkin, Skp1 
and PSMA2 (Burchell et al., 2013; Cenciarelli et al., 1999; Vingill et al., 2016). However, we wanted 
to get a full representation of FBXO7 interactome in the HEK 293T cell line, and link the 
interaction partners according to their function in the cell. In order to achieve this, I 
overexpressed FLAG-FBXO7 in HEK 293T cells, and using FLAG-beads, immunoprecipitated FBXO7 
together with all proteins and complexes it associates with and sent the samples for mass 
spectrometry analysis at the Proteomics Facility at the Medical Faculty of the RWTH Aachen (Fig. 
3.2 B). The proteins that were most enriched in the FBXO7 overexpressing cells were, as expected, 
part of the SCF complex, namely, the known interactors cul1, Skp1 and Rbx1 (Cenciarelli et al., 
1999), as well as proteins that associate to form the proteasome such as PSMA2, PSMA6, PSMB1, 
PSMB3 and PSMB4 (Fig. 3.2 A i) (Vingill et al., 2016). The second major cluster of proteins that 
were quite eminent are those involved in mitochondrial maintenance and cellular respiration (Fig. 
3.2 A ii). Proteins, responsible for cytoskeletal organization and maintenance as well as non-
clathrin mediated vesicular transport noticeably between the endoplasmic reticulum and the 
Golgi apparatus were also enriched in the mass spectrometry analysis (Fig. 3.2 A v, vi). 
Furthermore, there was an overrepresentation of protein and protein complexes involved in DNA 
repair as well as nuclear pore formation and transport (Fig. 3.2 A iii, iv). To further confirm the 
data from the mass spectrometry analysis, I went on to check some of the newly identified 
interactions. I selected two of the proteins from the DNA repair cluster, and performed a simple 
one-way co-immunoprecipitation using antibodies that would immunoprecipitate the targeted 
potential novel interaction partners of FBXO7 and observed a positive co-immunoprecipitation 
bands (Fig. 3.2 C).  
These findings simultaneously confirmed the known interaction partners and opened the 







Fig. 3.2  FBXO7 interactors predicted by quantitative mass spectrometry 
 (A) Network of FBXO7 interactors generated by using STRING database (http://string-db.org). The 
interactor list was obtained through mass spectrometry analysis of the 88 candidates and the data was fed 
into the STRING database. The interactors were then grouped according to their generalized function in the 
cells as follows: ubiquitination and proteasomal degradation (i ), mitochondrial maintenance (ii), DNA repair 
(iii ), formation of nuclear pores and protein transport (iv), cytoskeletal organization and remodeling (v), ER 
to Golgi vesicular transport (vi) and proteins with dual functionality (vii). (B) Western blotting of 50 g of 





The FLAG-FBXO7 was immunoprecipitated and sent for mass spectroscopy analysis  performed by Dr. 
Christian Preisinger at the Proteomics Facility at the RWTH Aachen. (C) Co-immunoprecipitation analysis 
represented in one blot showing the interaction between FBXO7 and two of its potential interactors. The 
proteins of interest were overexpressed in HEK 293T cells together with FLAG-FBXO7 control vectors. Cells 
were lysed ca. 72 hours after transfection and the lysates were subjected to immunoprecipitation with 
either anti-GFP or anti-Myc antibody. The interaction was detected by immunoblotting the membrane using 
anti-FLAG antibody. 50 g of the lysate were used as expressi on (anti-Myc, anti-GFP and anti-FLAG 
antibody) and loading (14-3-3 antibody) control. 
3.2. Biochemical analysis of the FBXO7-MAP1B LC1 interaction  
3.2.1. FBXO7 binds to the light chains of the MAP1 family 
In a yeast-two-hybrid assay using FBXO7 as bait, Dr. David Brockelt showed that amongst 
the known interaction partners, FBXO7 could also interact with the microtubule associated 
protein 1B light chain1 (MAP1B LC1) (Brockelt, 2015). Since the light chains of the MAP1s are 
highly homologous, Dr. Brockelt reasoned that FBXO7 may also interact with the other members 
of the MAP1 family. I re-confirmed these interactions by forward and reverse co-
immunoprecipitation followed by western blotting of FBXO7 together with MAP1B LC1 and 
MAP1B LC2 (Fig. 3.3 A-B). I also established that FBXO7 interacts with the light chain of the 
MAP1S (Fig. 3.3 C). Additionally I checked if there is interaction between FBXO7 and -synuclein, 
since both are encoded by PARK loci and it was previously found that FBXO7 interacts directly 
with PINK1 (PARK6) and Parkin (PARK2) (Burchell et al., 2013), but observed no interaction band 
on the western blot analysis after co-immunoprecipitating either FBXO7 or -synuclein (Fig. 3.3 
D). Taken together, these data establish MAP1S LC as novel interactor for FBXO7 and indicate that 







Fig. 3.3 FBXO7 interacts with the members of the MAP1 family but not with -synuclein 
(A-B) Forward and reverse co-immunoprecipitation represented in one blot showing the interaction 
between FBXO7 and MAP1B LC1 (A) or FBXO7 and MAP1A LC2 (B) performed by overexpressing of the 
proteins of interest and their respective cloning vectors as control in HEK 293T cells. Cells were lysed ca. 72 
hours after transfection and the lysates were subjected to immunoprecipitation  with the corresponding 
antibodies. The presence of the interaction partner was detected by immunoblot analysis  with the 
corresponding antibody. 50 g of the lysate was used for expression (anti -Myc antibody and anti-FLAG 
antibody) and loading (14-3-3 antibody) control. (C) Forward and reverse co-immunoprecipitation on 
different blots showing the interaction between FBXO7 and MAP1S LC, performed by overexpressing of the 
proteins of interest and their respective cloning vectors as control in HEK 293T cells. (D) Co-
immunoprecipitation assay performed by overexpressing -synuclein and FBXO7 and their respective 





were subjected to immunoprecipitation with the corresponding antibody. 50 mg of the lysate was used as 
expression (GFP and FLAG antibody) and loading (14-3-3 antibody) control.  
3.2.2. FBXO7 binds strongly to MAP1B LC1 independently of its SCF functions 
In order to see if the interaction would result in a functional modification of MAP1B LC1, I 
co-transfected empty, wild type or F-box construct of FBXO7 (lacking the F-box domain) 
together with MAP1B LC1. I observed, similarly to Dr. Brockelt, a slight increase in the signal for 
MAP1B LC1 every time I overexpressed the protein together with FBXO7 but not the control 
vectors. This is indicative that the stabilization of MAP1B LC1 is possibly susceptible to the 
FBXO7's ligase activity (Fig. 3.4 A). Since one of the main functions of FBXO7 is ubiquitin ligation 
to substrate proteins, I checked if in the presence of FBXO7, MAP1B LC1 gets ubiquitinated (Chang 
et al., 2006b). To test this, I overexpressed ubiquitin and MAP1B LC1 in all conditions, together 
with empty control vector, FBXO7 wild type plasmid or a FBXO7 version of the protein lacking its 
F-box domain, rendering it incapable of binding to the SCF complex. To avoid detection of the 
auto-ubiquitination signal of FBXO7, I subjected the lysates to a boiling protocol that I had 
previously established. Under these conditions, I observed no increase in the ubiquitin signal (Fig. 
3.4 B). Furthermore, the immunoblotting corresponding to MAP1B LC1 was again stronger and 
had multiple bands whenever FBXO7 and MAP1B LC1 were co-expressed, but not when MAP1B 
LC1 was co-expressed with the empty vector or with the FBXO7 F-box construct (Fig. 3.4 B). 
To further confirm that the interaction between FBXO7 and MAP1B LC1 does not lead to 
the ubiquitination of the substrate, I checked if it is dependent on the formation of the SCF 
complex. Therefore, I performed another co-immunoprecipitation analysis in which I 
immunoprecipitated either FBXO7 or MAP1B LC1 using either anti-FLAG or anti-Myc antibody (Fig. 
3.4 C). I then blotted the membrane to check for the presence of cul1, since cul1 is the main 
scaffolding protein of the SCF complex (Fig. 3.4 C) (Willems et al., 2004). I was able to detect 
signal whenever I immunoprecipitated the FBXO7 protein but the signal was absent when I 
immunoprecipitated the MAP1B LC1 indicating that MAP1B LC1 does not interact with the 
cytoplasmic FBXO7 associated with the SCF-complex (Fig. 3.4 C). I went on to further show that 
the interaction between FBXO7 and MAP1B LC1 was still present by stripping the membranes and 
reblotting them with either anti-FLAG or anti-Myc antibody (Fig. 3.4 C). In summary, MAP1B LC1 
stabilization is influenced by FBXO7 in HEK 293T cells, and the interaction between these two 






Whilst standardizing the boiling steps of the ubiquitination assay, I realized that the 
interaction between FBXO7 and MAP1B LC1 is quite strong as I needed a higher than usual 
concentration of SDS and up to 30 min of boiling to disrupt the interaction. Therefore, I asked 
whether the strength of this interaction is altered in the known pathological mutants of FBXO7. I 
subjected the lysates to similar protocol as the boiling protocol, except, I used 1.0% of the SDS 
instead of 1.5% to avoid complete loss of the signal. I observed that the interaction remained 
strong in all mutants except for the M115I (Fig. 3.4 D). However, the expression control blotting 
revealed that this interaction decreases also the MAP1B LC1 stability and thus the band for 
MAP1B LC1 was of similar thickness as the control band (Fig. 3.4 D). 
These results corroborated previous findings in our lab and further enhanced our 
knowledge on the non-E3 ligase dependant interaction between FBXO7 and MAP1B LC1 and the 






Fig. 3.4  FBXO7 interacts with the MAP1B LC1 proteins independent of its ligase activity 
(A) Representative western blot analysis of the effect of co-expressing FBXO7 together with MAP1B LC1. 50 
g of HEK 293T cells lysate either overexpressing control, wild type or F-box variant of FBXO7 and MAP1B 
LC1 were immunoblotted using the anti -Myc and the anti -FLAG antibody respectively. (B) Ubiquitination 
assay of MAP1B LC1. HEK 293T cells were transfected either with control vector, FBXO7 wild type or a F-
box FBXO7 together with HA-Ubiquitin and MAP1B LC1. The cells were lysed using RIPA buffer and 
subjected to incubation with 1.5% SDS for 10 min at RT and then 30 min at 95
oC. The presence of ubiquitin 
was tested by immunoblotting the membrane with anti -HA antibody. 50 g of the lysate was used for 
expression and loading control. (C) Representative co-immunoprecipitation analysis showing the interaction 
between FBXO7 and MAP1B LC1 with cul1, performed by overexpressing myc -FBXO7 and FLAG-MAP1B LC1  
in HEK 293T cells. Cells were lysed ca. 72 hours after transfection and the lysates were subjected to 
immunoprecipitation with the corresponding antibody. The presenc e of the interaction partner was 





for expression (anti -Myc antibody and anti -FLAG antibody) and loading (14-3-3 antibody) control.  The 
membranes were then subjected to stripping and re-blotting with the indicated antibodies. (D) 
Representative co-immunoprecipitation blot showing the interaction between MAP1B LC1 and different 
known mutations of FBXO7. The mutated FBXO7 plasmids were trans fected together with MAP1B LC1 in 
HEK 293T cells. Cells were lysed and subjected to immunoprecipitation using anti -FLAG antibody. The 
presence of the interaction partner was detected by immunoblotting the membrane with the anti -myc 
antibody. 50 g of the lysate was used for expression (anti -Myc antibody and anti -FLAG antibody) and 
loading (14-3-3 antibody) control.   
3.3. Cellular pathways influenced by FBXO7 and MAP1B LC1  
Once the interaction was established, I wondered which cellular processes would be 
influenced and what is the molecular relevance of the knockdown of the proteins. I performed a 
series of experiments trying to illuminate the role of both FBXO1 and MAP1B LC1 in the cell, 
starting with an all-encompassing mass spectroscopy analysis and then diving down to cellular 
and organellar morphology. 
3.3.1. Mass Spectroscopy analysis of the MAP1B LC1 pull down enriched for FBXO7 
hints for mitochondrial involvement   
Since the interaction between MAP1B LC1 and FBXO7 was confirmed, we wanted to see 
which proteins would be upregulated in the presence of both proteins. In order to do this, I 
transfected HEK 293T cells with FBXO7 and MAP1B LC1, immunoprecipitated for the MAP1B LC1 
and sent the samples for mass spec analysis at the Proteomics Facility at the RWTH Aachen (Fig. 
3.5 B). The resulting list contained different protein members responsible for ubiquitination of 
proteins, which was expected since the cells were transfected with FBXO7: an E3 ubiquitin ligase. I 
also saw an increase in cytoskeletal subunits, again an expected result, since I overexpressed 
MAP1B LC1, whose main function is cytoskeletal stabilization (Togel et al., 1998b). Interestingly, 
there was a large group of proteins that are involved in mitochondrial homeostasis and metabolic 







Fig. 3.5  The FBXO7-MAP1B interaction: novel involvement in mitochondrial health and DNA 
processing 
 (A) Networks of FBXO7-MAP1B LC1 enrichment experiment generated by using STRING database 
(http://string-db.org). The protein list was obtained through mass spectrometry analysis and 26 candidates 
with the highest peptide concentration ratio were picked and fed into the STRING database. The proteins 
were then grouped according to their generalized function in the cells as follows: ubiquitinatio n and 
proteasomal degradation (i), DNA repair and transcription (ii), mitochondrial maintenance and (iii ) 
cytoskeletal assembly (iv). (B) Western blotting of 50 g of input obtained from the lysis of HEK 293T cells 
overexpressing either empty Myc-vector together with FLAG-MAP1B LC1 or Myc-FBXO7 together with 
FLAG-MAP1B LC1. The FLAG-MAP1B LC1 was immunoprecipitated using FLAG beads  and sent for mass 
spectroscopy analysis.  The 14-3-3 antibody was used as loading control. 
3.3.2. FBXO7 is required for the proper dendritogenesis 
As mentioned in the introduction, FBXO7 is a protein with multiple cellular functions 
ranging from mitophagy, cell cycle and proteasome regulation to sperm production in Drosophila 
melanogaster (Burchell et al., 2013; Kirk et al., 2008; Laman et al., 2005; Vingill et al., 2016).  
Having such diverse involvement in major cellular processes, as well as my previous results linking 
FBXO7 to the cytoskeleton, I went on to characterize the gross morphology of neurons lacking 
FBXO7. I transfected rat cortical neurons with control plasmids or FBXO7 shRNA together with - 
galactosidase as transfection marker and subjected them to immunocytochemical staining (Fig. 
3.6 A). Finally, I measured the average axonal and total dendritic lengths of at least 40 neurons 





marked decrease by almost half in the average total dendritic length as well at the average 
number of dendrites in neurons transfected with the functional FBXO7 shRNA compared to 
control neurons (Fig. 3.6 C, D). These results point to a novel role of FBXO7 in dendritic 
arborization and outgrowth. 
 
Fig. 3.6 FBXO7 knockdown results in fewer and shorter dendrites 
 (A) Representative images of (P0) rat cortical neurons transfected at DIV1 with either control or FBXO7 
shRNA vectors together with a -galactosidase encoding plasmid serving as transfection marker. The 
neurons were fixed and stained at DIV6 using anti--galactosidase antibody as primary antibody, followed 
by Cy2-conjugated antibody. Magnification: 20x. Scale bar = 100 m. (B) Quantification and statistical 
analysis of the average axonal length using one-way ANOVA (N=3, mean + s.e.m.) (C) Quantification and 
statistical analysis of the average total dendritic length using one-way ANOVA (N=4,*P<0.5; **P<0.01, mean 
+ s.e.m.) (D) Quantification and statistical analysis of the average dendritic number per cell  using one-way 








3.3.3. Knockdown of FBXO7 leads to mitochondrial fragmentation 
As previously noted, FBXO7 was also found to play a role in regulation of mitophagy, where 
misregulated mitochondrial clearance results in mitochondrial depolarization (Delgado-Camprubi 
et al., 2017; Zhou et al., 2015). Furthermore, disruptions in mitochondrial homeostasis and 
maintenance have been the cellular hallmark for PD. I used mitochondrial morphology as a read-
out for healthy vs. aberrant organelles and tested whether FBXO7 leads to mitochondrial 
fragmentation. I co-transfected HEK 293T cells with FBXO7 shRNA together with a GFP tagged 
ornithine transcarbamylase (OCT) that is expressed in the inner mitochondrial membrane (IMM), 
serving as mitochondrial marker (Henslee and Srere, 1979; Munch and Harper, 2016). By 
immunoblotting whole cell extracts, I confirmed that the FBXO7 shRNA sufficiently blocks the 
expression of the targeted protein (Fig. 3.7 B). I classified the mitochondria into three categories 
based on their morphological appearance: tubular, globular and fragmented (Fig. 3.7 A). After 
analyzing a minimum of 100 cells per condition, I saw a significant increase in the number of HEK 
293T cells with fragmented mitochondria at the expense of cells containing tubular organelles in 
the FBXO7 knockdown condition in comparison to control (Fig. 3.7 C). Furthermore, there was no 
change in the number of cells with globular mitochondria.  
To check if this is a general consequence of FBXO7 knockdown and if mitochondrial 
morphology is influenced by FBXO7 in neuronal cells, I repeated the experiment in immortalized 
neuroblastoma SH-SY5Y cells. I transfected the cells using Lipofectamine 2000 for maximal 
transfection rate with the same plasmids and categorized the mitochondria as previously 
described (Fig. 3.7 D). I did not see any significant difference in the mitochondrial morphology of 
cells (Fig. 3.7 F). To ensure that this was not due to a lack of FBXO7 expression in the SH-SY5Y cell 
line, I also checked for the presence of FBXO7 in these cells at different times of passaging by 
western blotting, and detected a clear band confirming the endogenous FBXO7 expression in SH-
SY5Y (Fig. 3.7 E). These data taken together indicate that FBXO7 may play a protective role in 












Fig. 3.7 Effect of FBXO7 knockdown in mitochondria 
(A) Representative images of HEK 293T cells transfected at DIV3 with either control or FBXO7 shRNA vectors 
together with OCT-GFP expression plasmid serving as mitochondrial  marker. The cells were fixed and 
stained at DIV8 using DAPI as nuclear counterstain. Magnification: 60x. Scale bar = 100 m. (B)  
Quantification and statistical analysis of minimum 100 cells per condition with their mitochondria 
categorized as either tubular in appearance, globular or fragmented, using one-way ANOVA after 
normalization (N=3,*P<0.5; mean + s.e.m.) (C) Proof for the FBXO7 shRNA functionality. HEK 293T cells 
were transfected with FBXO7 and either empty control vector or the functional FBXO7 shRNA. After lysis 
the samples were subjected to immunoblotting with the anti -Myc antibody. The 14-3-3 antibody served as 
loading control. (D) Representative images of SH-SY5Y cells transfected at DIV1 with either control or FBXO7 
shRNA vectors together with OCT-GFP plasmid serving as mitochondrial  marker. The c ells were fixed and 
stained at DIV4. Magnification: 60x. Scale bar = 100 m. (E) Western blotting of SH-SY5Y cell  lysates of 
different passages using endogenous FBXO7 antibody and the 14-3-3 as loading control. (F) Quantification 
and statistical analysis of minimum 100 cells per condition with their mitochondria characterized as either 
tubular in appearance, globular or fragmented, using one-way ANOVA after normalization (N=3; mean + 
s.e.m.)  
3.3.4. MAP1B LC1 is expressed in cortical neurons at least from P4-P8 
Since we characterized MAP1B LC1 as a putative interactor to FBXO7, I went on to study 
and compare the expression patterns and functions of MAP1B LC1 in cortical and immortalized 
SH-SY5Y neurons to see if I can find a common pathway for these two novel interactors. 
The exact window of expression of MAP1B LC1 has never been clearly defined. It is known 
to be highly expressed at the peak of axonal growth and synaptic guidance, but the levels of 
expression fall off as the neurons mature (Viereck et al., 1989). In order to better define the 
timing of expression of MAP1B LC1, I cultured P0 mouse cortical neurons and fixed them at 
different time points. I then stained them for endogenous MAP1B LC1 and observed that at all 
three time points- DIV4, 6 and 8 there was a clear signal for the protein's expression in the 








Fig. 3.8 MAP1B LC1 is expressed in cultured mouse cortical neurons at least up to DIV8  
Representative images of mouse cortical neurons cultured at P0, and fixed at either DIV4, 6 or 8. The cells 
were then subjected to immunocytochemical staining using anti MAP1B LC1 antibody and then Cy3  as 
secondary antibody together with DAPI. Magnification: 60x. Scale bar = 20 m.  
3.3.5. MAP1B LC1 knockdown in SH-SY5Y cells does not lead to increased 
fragmentation of mitochondria  
MAP1B LC1 has been linked primarily with axonal growth and guidance (Matus, 1988) In 
addition, it has been recently found to play a role in stress-mediated mitochondrial functionality 
(Yonashiro et al., 2012) and MAP1B has been shown to regulate the retrograde mitochondrial 
transport through the axon (Jimenez-Mateos et al., 2006). Together with the fact that MAP1B LC1 
strongly interacts with FBXO7, I asked if MAP1B LC1 alone has influence on the mitochondrial 
maintenance. To check that, I transfected SH-SY5Y cells with control vectors and functional 
MAP1B LC1 shRNA that I had synthesized previously (Fig. 3.9 C). Similarly to the experiments in 
Section 3.3.3, I used OCT-GFP as mitochondrial marker and after staining I categorized the 
mitochondria of a minimum of 100 cells as either having tubular, globular or fragmented 





mitochondria, but I saw fewer cells with healthy and tubular mitochondria in the knockdown 
condition in comparison to the control MAP1B LC1 shRNA (Fig. 3.9 A-B). Interestingly, when I 
checked for endogenous expression of MAP1B LC1, I could not detect any signal in the SH-SY5Y 
cells, possibly due to the fact that the antibody does not recognize the human antigen (Fig. 3.9 D). 
In summary, FBXO7 lead to increase in fragmented mitochondria in HEK 293T cells but the 
knockdown of FBXO7 and MAP1B LC1 resulted in none or only slight decrease in tubular 
organelles in neuroblastoma SH-SY5Y cells. 
 
Fig. 3.9 Mitochondrial morphology of SH-SY5Y is largely unaffected after knockdown of 
MAP1B LC1 
 (A) Representative images of SH-SY5Y c ells transfected at DIV1 with either control or MAP1B LC1 shRNA 





DIV3. Magnification: 60x. Scale bar = 20 m. (B) Quantification and statistical analysis of minimum 100 cells 
per condition with their mitochondria characterized as either tubular in appearance, globular or 
fragmented, using one-way ANOVA after normalization (N=3,*P<0.5 ; mean + s.e.m.) (C) Proof for the 
MAP1B LC1 shRNA functionality. HEK 293T cells were transfected with MAP1B LC1 and either empty control 
vector or the functional MAP1B LC1 shRNA. After lysis the samples were ran on SDS-PAGE and subjected to 
immunoblotting with the anti-FLAG antibody. 14-3-3 antibody served as loading control. (D) 
Representative images of SH-SY5Y cells, fixed and stained using anti MAP1B LC1 antibody as primary and 
Cy3 as secondary antibody together with DAPI at DIV3. Magnification: 60x. Scale bar = 20  m.  
3.4.  In vivo analysis of the role of FBXO7 in the neocortex and the 
pyramidal tracts 
Systemic loss of FBXO7 was shown to lead to a severely detrimental phenotype, most 
notably decreased body size and survivability (Vingill et al., 2016). The Fbxo7-/- mice would not live 
longer than 25 days and the mean age of death is 18 days, making further analysis on these mice 
difficult (Vingill et al., 2016). In order to gain a better insight into the effects of FBXO7 in the 
nervous system, different mouse lines were generated previously in the lab, targeting the deletion 
of FBXO7 to different brain areas and cell types. The NEX-Cre/Fbxo7fl/fl mouse line has the Cre 
recombinase expressed under the neuronal basic helix-loop-helix (NEX) protein, allowing for the 
spatial control of Fbxo7 deletion (Goebbels et al., 2006; Vingill et al., 2016). Thus, the Fbxo7 is 
deleted from the neocortex and hippocampus- more specifically, the pyramidal neurons of the 
dorsal telencephalon and the mossy and granule cells in the dentate gyrus, sparing interneurons, 
oligodendrocytes and astrocytes (Goebbels et al., 2006). These mice survived much longer, and 
the body weight at 2 months of age was comparable to their wild type littermates allowing for 
further motor and behavior studies (Vingill et al., 2016). 
Genotyping analysis of the NEX-Cre/Fbxo7fl/fl was performed on regular basis to ensure 
setting of the correct breedings and experimental setup (Fig. 3.10 A-B). The NEX-Cre and the 
Fbxo7fl/fl mice were used as controls, since the NEX-Cre mice lack the floxed Fbxo7 allele or the 
Fbxo7fl/fl mice would lack expression of the Cre-recombinase respectively rendering both 






Fig. 3.10 Transgenetic mapping of the Fbxo7fl/fl construct. 
(A) Schematics of the wild type allele, containing nine exons, and the insertion of the transgenic construct 
through homologous recombination that leads to the truncation of the protein. The construct contains FRT1 
and FRT2 sites, used to excise the -galactosidase (LacZ reporter) and the -actin::neomycin selection 
cassette, as well as loxP sites flanking exon 4. (B) Genotyping PCR of the NEX-Cre;Fbxo7
fl/fl 
, where the 
presence of the NEX-Cre was detected using Cre forward and reverse primers, and the presenc e or absence 
of transgenic allele was tested by using the wildtype primers (representative image was kindly provided by 
Sabitha Joseph). 
3.4.1. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay (TUNEL) 
analysis reveals no increase in cellular apoptosis   
Neuronal death is the hallmark for neurodegenerative diseases. Since neuronal  loss was 
observed in the conventional knockout model, I wondered if I would also observe similar 
phenotype in the NEX-Cre;Fbxo7fl/fl mice at 8 weeks of age, since they already exhibited a motor 
phenotype at this stage (Vingill et al., 2016). To answer this question, I performed TUNEL assay, 
which takes advantage of the fact that cells undergoing apoptosis have their DNA nicked and 
fragmented and the terminal deoxynucleotidyl transferase (TdT) binds to the 3'-OH of the 
fragmented DNA, further incorporating biotinylated deoxyuridines to the sites of breakage 
(Gavrieli et al., 1992). These can then be further labeled and visualized by using chromogens such 





which appeared brown in color. In total, three mice per genotype were compared for biological 
triplication as well as three technical replicates for each brain. I then compared the number of 
apoptotic cells in the cortex, the hippocampus and the cerebellum, where the latter served as 
control, since FBXO7 is expressed in the cerebellum in the NEX-Cre;Fbxo7fl/fl mice. I saw a slight 
tendency for an increase in apoptosis in the NEX-Cre;Fbxo7fl/fl mice in all three brain regions 
tested, however this is statistically insignificant because of the very low count of apoptotic cells at 
this age (Fig. 3.11 A-C). I also measured the total cerebellar and cortical area of all three mouse 
genotypes with a total of 6 animals tested per genotype. After running one-way ANOVA statistical 
test, I saw that the cerebellar area remains comparable within all three genotypes, but there is 
significant decrease in the cortical area when comparing the NEX-Cre and the NEX-Cre;Fbxo7fl/fl 
mice, and only a  tendency when comparing the NEX-Cre;Fbxo7fl/fl mice with the Fbxo7fl/fl (Fig. 3.11 
D). These data indicate that albeit there is no cellular death ongoing in 8-week old animals, the 








Fig. 3.11 There is no increased level of apoptosis in the cortex of NEX-Cre;Fbxo7fl/fl mice 
(A) Immunohistological representative images from the cerebellum, hippocampus and cortex of 5 m thick 
sagittal sections from 8-weeks old NEX-Cre;Fbxo7
fl/fl
 and control mice. The red arrows point at nuclei that 
have stained positive with the TUNEL assay detection kit. Magnification: 40x. Scale bar = 100 m. (B)  
Quantification of the TUNEL assay: the total number of apoptotic cells was counted and normalized to the 
area of interest and subjected to statistical analysis using the One-way ANOVA test (N=3; mean + s.e.m.) (C) 
Quantification of the total cortical or cerebellar area (mm
2
) of the NEX-Cre;Fbxo7fl/fl , Nex-Cre and Fbxo7fl/fl 





3.4.2. The NEX-Cre;Fbxo7fl/fl mice present with increased astrogliosis and 
inflammation 
Gliosis is a process that occurs after a brain injury, and its main components- astrogliosis 
and microgliosis have been known to be dependent of each other in neurodegenerative diseases 
(Tong et al., 2015). In order to test whether there will be similar pathological signs in the  NEX-
Cre;Fbxo7fl/fl mice, I subjected paraffin brain sections to either glial fibrillary acidic protein (GFAP) 
or  Ionized calcium-binding adapter molecule 1 (Iba1) immunohistological stainings. The GFAP was 
used as a marker for astrogliosis, and the Iba1 was used as a marker for inflammatory response, 
since these antibodies stain the astrocytes or microglia respectively. The NEX-Cre;Fbxo7fl/fl mice 
showed significantly increased signal corresponding to GFAP positive cells, both in the cortex as 
well as in the cerebellum (Fig. 3.12 A,C). The count of Iba1 positive cells was also significantly 
greater in the NEX-Cre;Fbxo7fl/fl  compared to their littermates specifically in the cortex, where the 
count remained comparable within the cerebellum (Fig. 3.12 B,D). The increase in signal of these 
markers present in the immunohistological sections indicate that there has been a major brain 







Fig. 3.12 The NEX-Cre;Fbxo7fl/fl show increased astrogliosis and inflammatory cell number in the 
cortex 
 (A) Immunohistological staining using anti -GFAP antibody on 5 m sagittal brain sections. The 
representative images are taken from cerebellar and cortical areas from the NEX-Cre;Fbxo7
fl/fl







 mice. Magnification: 40x. Scale bar = 100 m. (B) Immunohistological staining using anti -Iba1 
antibody. The representative images are taken form cerebellar and cortical areas form the NEX-
Cre;Fbxo7
fl/fl
, NEX-Cre and the Fbxo7
fl/fl 
mice. Magnification: 40x. Scale bar = 100 m. (C)  Quantification and 
statistical analysis of GFAP positive area, comparing the cortex and cerebellum within all  three genotypes 
using One-way ANOVA (N=3; **P<0.01, ***P<0.001, mean + s.e.m.) (D) Quantification and statistical 
analysis of Iba1 positive cells  and normalized to the area of interest and subjected to statistical analysis 
using the One-way ANOVA test (N=3, *P<0.5 ; **P<0.01, mean + s.e.m.)  
3.4.3. NEX-Cre;Fbxo7fl/fl mice have intact pyramidal tracts with no 
neurofilamentous inclusions 
Axonal injury causes a decrease in expression level of the Neurofilament medium (NFM) 
protein (Bisby et al., 1995). This has also been observed in neurodegenerative diseases including 
Parkinson's Disease together with deposition of neurofilaments forming neurofilamentous 
inclusions (Julien and Mushynski, 1998). Furthermore, neurofilaments are the major constituent 
of the cytoskeleton comprising the axon cylinder (Black and Lee, 1988). I therefore subjected the 
brain sections to NFM staining, and saw no visible difference in the pyramidal tracts of the NEX-
Cre;Fbxo7fl/fl mice in comparison to the control groups (Fig. 3.13 A).  
The majority of patients with the parkinsonian pyramidal syndrome have reported 
pyramidal tract signs (Table 1.1) (Di Fonzo et al., 2009). I therefore stained for the amyloid 
precursor protein (APP) on the brain paraffin sections of the 8 week-old animals of the three 
genotypes, to check the integrity of the tracts. APP is synthesized in the soma and transported to 
the axonal terminus, where in case of axonal injury it will be accumulated at the point of 
cytoskeletal aberration and appears as bulbous structures or axonal swellings (Sherriff et al., 
1994). The knocking out of Fbxo7 from the forebrain had no visible effect on the pyramidal axonal 
tract structure (Fig. 3.13 B).  
These results imply that the pyramidal tract symptoms are not represented in the gross 
histological analysis of the 8 week-old NEX-Cre;Fbxo7fl/fl mice, raising the possibility that these 






       
 
Fig. 3.13 Axons in the pyramidal tract remain unaltered and healthy 
(A) Immunohistological staining using anti -NFM antibody on 5 m sagittal brain sections of NEX-
Cre;Fbxo7
fl/fl 
, NEX-Cre and the Fbxo7
fl/fl 
mice. The representative images are taken from the ventral 
pyramidal tract area. Magnification: 40x. Scale bar = 100 m.  (B) Immunohistological staining using anti -
APP antibody on 5 m sagittal brain sections of NEX-Cre;Fbxo7
fl/fl 
, NEX-Cre and the Fbxo7
fl/fl 
mice. The 
representative images are taken from the ventral pyramidal tract area. Magnification: 40x. Scale bar = 100 
m.   
3.4.4. NEX-Cre;Fbxo7fl/fl  mice do not present with Lewy body pathology 
Hallmark of idiopathic PD is the presence of Lewy body inclusions whose main constituent 
is -synuclein (Forno and Norville, 1976). I therefore screened for the presence of proteinase K 
resistant -synuclein aggregations and saw no difference in the morphology of the brains of the 
NEX-Cre;Fbxo7fl/fl compared to their littermates (Fig. 3.14). These data indicate that deletion of 






Fig. 3.14 There is no Lewy body pathology in the NEX-Cre;Fbxo7fl/fl mice 
Immunohistological staining using anti --synuclein antibody on 5 m sagittal pre-digested with Proteinase 
K brain sections of NEX-Cre;Fbxo7
fl/fl 
, NEX-Cre and the Fbxo7
fl/fl 
mice. The representative images are taken 






















Autosomal recessive mutations in the Fbxo7 gene were first discovered and related to the 
Parkinsonian-pyramidal syndrome later known as late onset parkinsonism by Shojaee et al. in 
2008 (Shojaee et al., 2008). Their findings were then further substantiated and up to date there 
are about 6 well-studied kindreds that harbor a variety of mutations in the Fbxo7 gene. Almost a 
decade later, scientists have managed to link FBXO7 with major players in the mitophagy 
pathway, as well as the ubiquitin-proteasome system, which are in turn considered to be at the 
forefront of neurodegenration. Even though only a small fraction of the PD cases are genetically 
inherited, we study FBXO7, its interactome, its functions in cel l and tissue to hopefully improve 
our understanding of the causes of neurodegeneration and pathological progression of idiopathic 
and non-idiopathic cases of PD. The main aim of this study is to unravel the molecular 
mechanisms involving FBXO7 and its interaction partners by the use of genetics, biochemistry, 
analytical chemistry and histology. Amongst the many interaction partners for FBXO7 that we 
identified through quantitative mass spectrometry and yeast-two-hybrid assay preformed 
previously in the lab, I focused on the light chain of the microtubule associated protein 1B 
(MAP1B LC1). I went on to characterize the type of interaction between these two proteins, and 
found that it is independent of the SCF-complex formation. I further tested how loss-of-function 
of both proteins would affect the mitochondrial morphology in cells and observed slight changes 
in this read-out. Finally, I also studied the consequences of the loss of FBXO7 from the neocortex, 
and found an up-regulation of astro- and microglial markers, indicative of generalized tissue 
response for brain injury in the absence of apoptosis. These results help to expand our knowledge 
on FBXO7 and the molecular mechanism for pathology in neurodegenerative disorders. 
4.1. FBXO7 is a cytoplasmic protein  
One important question to be answered when studying a protein is i ts localization within 
the cell. Zhao et al. overexpressed wild type untagged FBXO7 in HEK 293T, SH-SY5Y cells and 
mouse primary hippocampal neurons and concluded that FBXO7 localized predominantly to the 
nucleus, especially in the immortalized cell lines (Zhao et al., 2011).  Arguably, the representative 
figures for the wild type FBXO7 overexpression in the hippocampal neurons clearly depicts FBXO7 
in the cytoplasm as well (Zhao et al., 2011). They also obtained patients' fibroblasts harboring the 
T22M mutation as well as healthy control fibroblasts and examined for endogenous FBXO7 
protein, where they saw cytoplasmic signal for the T22M mutation and diffuse nuclear signal in 





FBXO7 (Zhao et al., 2011). Interestingly, the specificity of the antibody they used was tested using 
western blotting, even though the results were obtained thought immunocytochemical analysis 
(Zhao et al., 2011). Our research group wanted to further substantiate these findings by 
performing a subcellular fractionation of cortical lysates, since the available commercial 
antibodies were not able to detect endogenous FBXO7 by immunocytochemistry. The subcellular 
fractionation analysis of Fbxo7-/-, Fbxo7+/- and Fbxo7+/+ of P18 brain lysates showed clearly that 
FBXO7 localizes to cytoplasmic fraction and not the nuclear fraction (Brockelt, 2015). I went on to 
further validate the cytoplasmic localization of FBXO7 in neurons as well as in HEK 293T and SH-
SY5Y cells by immunocytochemistry. I saw that nearly all healthy cells expressed the FBXO7 
protein in the cytoplasm. This observation is also in line with the subcellular localization of FBXO7 
and also, almost all of the known functions and interactors of FBXO7 within neurons such as 
HURP, PINK1, Parkin, Skp1, PSMA2, Tomm20 etc. are found in the cytoplasm (Hsu et al., 2004; 
Nelson et al., 2013; Teixeira et al., 2016; Vingill et al., 2016). These observations are further 
supported by the findings of Nelson and Laman who showed in U2OS cells that FBXO7 localized to 
the cytoplasm but is shuttled to the nucleus specifically when the cells entered the G1/S transition 
(Nelson and Laman, 2011). This shuttling might be due to the fact that FBXO7 plays an important 
role in cell cycle regulation in mitotic cells such as haematopoietic stem cells and fibroblasts by 
acting as an assembly scaffold for the cyclin D/Cdk6 complex which are in turn G1/S transition 
state regulators (Cheng et al., 1999; Meziane el et al., 2011). However, the vast majority of 
neurons are post-mitotic cells that are in their resting G0 phase, further on validating all findings 
that FBXO7 localizes to the cytoplasm. 
4.2. FBXO7 can be linked to a plethora of cellular mechanisms.  
As previously mentioned, FBXO7 has several well established interaction partners in 
relation to its role in neurodegeneration- PINK1, Parkin and Tomm20 on one hand (Burchell et al., 
2013; Teixeira et al., 2016) and Skp1 together with different subunits of the proteasomal 
holoenzyme on the other (Cenciarelli et al., 1999; Vingill et al., 2016). These proteins can be 
grouped into two main categories, namely those being part of the mitochondrial maintenance 
machinery or of the ubiquitin proteasome system (UPS) (Nelson et al., 2013). Upon performing a 
quantitative mass spectrometry analysis in collaboration with the Proteomics Facility at the RWTH 
Aachen, we obtained the interactome of FBXO7. I focused on a total of 88 targets omitting 
candidates whose high enrichment readouts could be due to contamination such as keratin. 
These proteins could be then arranged in six groups according to their function in the cell. Apart 





also yielded a list of proteins involved in DNA repair,  formation of nuclear pores, nuclear pore 
transport, microtubular organization and dynamics as well as endoplasmic reticulum (ER) to Golgi 
non-clathrin mediated vesicular transport. Since FBXO7 does shuttle between the nucleus and the 
cytoplasm, regulates the cellular cycle, and recently was found to be  a putative up-stream 
activator of the DNA-repair enzyme PARP, the increase in signal for proteins and protein 
complexes involved in these processes does not come as a surprise (Cheng et al., 1999; Delgado-
Camprubi et al., 2017; Meziane el et al., 2011; Nelson and Laman, 2011). Furthermore, I 
confirmed the mass spectrometry data regarding two of the novel interactors in a cell-based co-
immunoprecipitation analysis. Interestingly, the involvement in cytoskeleton organization and 
remodeling as well as vesicular transport might point to novel functions of FBXO7. One 
explanation for the abundance of the latter can be the fact that Skp1 binds to the F-box protein 
Rcy1 to mediate early endosome to trans-Golgi protein recycling and since the Skp1 presence in 
the mass spectromety analysis was very high, it is possible that some of the Skp1 was also bound 
to Rcy1 (Galan et al., 2001). However, since many of the putative interaction partners are involved 
in ER to Golgi trafficking, this interaction can be considered as novel and as the starting point of a 
new line of research. 
 A very dominant family of proteins that are being represented in the mass spectroscopy 
data is the tubulin family. The closest reports associating FBXO7 and the cytoskeleton came from 
a large scale in vitro ubiquitination experiment, fishing for novel substrates of FBXO7-SCF where 
10 of the 338 substrates were localized at the microtubular organizing center (Teixeira et al., 
2016). The microtubule associated protein 1B light chain1 (MAP1B LC1) was identified as novel 
putative interactor to FBXO7 as shown in a yeast-two hybrid analysis performed previously in our 
laboratory (Brockelt, 2015). These discoveries unlocked the possibility to study the effect of the 
cytoskeleton-microtubule-UPS triangle that may ultimately contribute to neurodegeneration. 
4.3. The MAP1B LC1-FBXO7 interaction results in non FBXO7-SCF-
dependent functional modification     
In his thesis, Dr. Brockelt confirmed the interaction between FBXO7 and the MAP1B LC1 of 
the yeast-two-hybrid assay also through cell-based co-immunoprecipitation analysis (Brockelt, 
2015). I repeated his experiments, showing that FBXO7 indeed associates with MAP1B LC1. Since 
the light chains of MAP1A and MAP1B are highly homologous, Dr. Brockelt reasoned that FBXO7 
should be able to interact with the light chains of the MAP1 family (Langkopf et al., 1992) 
(Brockelt, 2015). This was shown for the MAP1A LC2 by Dr. Brockelt and further confirmed by my 





pCMV10-3xFLAG-MAP1B LC1 expression vector, and proved the interaction also in a cell-based 
co-immunoprecipitation analysis. The interaction site was found to lie somewhere between 
amino acids 78 and 180 of the FBXO7 protein (Brockelt, 2015). There are two interaction partners 
that use this amino acid stretch for their association with FBXO7- namely the PINK1, an important 
regulator of mitophagy, and the Cdk6 (Burchell et al., 2013; Laman et al., 2005). Intriguingly, I 
found that from all known pathological mutations of FBXO7, the M115I single nucleotide 
polymorphism (SNP), located within this interaction sequence, results in weaker interaction 
strength between FBXO7 and MAP1B LC1. However, this can be due to the fact that this 
interaction did not result in the usual stabilization of MAP1B LC1 by FBXO7 (as discussed in the 
following paragraph), and that there was less protein for the co-immunoprecipitation analysis, 
thus weaker band is apparent on the western blot. This SNP lies within the FBXO7-PINK1 
interaction domain, suggesting that the association between MAP1B LC1 and FBXO7 may be 
important for the maintenance of proper mitochondrial quality control. It is interesting to note 
that the methionine required for initiation of translation of FBXO7 isoform 3 is located at this site, 
and this M115I SNP would result in abolished expression of isoform 3 (Nelson et al., 2013). 
Unfortunately, the M115I SNP is the least excessively studied Fbxo7-related pathological variation 
and it is mostly associated with haematopoiesis, and further analysis is necessary in order to 
uncover the significance of this interaction (Chen et al., 2014; Ding et al., 2012; Soranzo et al., 
2009; van der Harst et al., 2012).  
The co-expression of FBXO7 and MAP1B, consistently resulted in a much stronger western 
blot signal compared to MAP1B LC1 co-expressed with the empty vector. The band was also 
slightly stronger but not as dramatic when MAP1B LC1 was co-expressed with the F-box FBXO7 
construct that is devoid of its ligase activity. These results might indicate that since FBXO7 is a 
main component of the FBXO7-SCF-ubiquitin ligase complex, the interaction leads to a functional 
modification of MAP1B LC1 and we reasoned that most probably, this modification is 
ubiquitination (Cenciarelli et al., 1999). To check this hypothesis, I performed cell -based 
ubiquitination assay, but did not observe the typical smear in the condition where I overexpressed 
both proteins in comparison to controls. This observation points to the conclusion that MAP1B 
LC1 does not get polyubiquitinated by FBXO7. Furthermore, the heavy immunoglobulin chains of 
the primary antibody may have hidden a signal that could correspond to a mono-ubiquitination of 
MAP1B LC1.  Instead of long chains of ubiquitin with different lengths, resulting in a smear, in 
mono-ubiquitination the protein gets modified by only a single ubiquitin molecule  which would 
appear as a single band on the western blot analysis. To test for this possibility, I checked whether 





complex. I used cullin1 as a protein of choice to probe whether MAP1B LC1 is capable to pull 
down FBXO7 together with the rest of the components of the SCF complex. Indeed, MAP1B LC1 
was not able to recruit the FBXO7 proteins associated with the Skp1-cul1 complex, but could 
recruit FBXO7 that are not a part of the E3 ubiquitin ligase complex. These data imply that FBXO7 
and MAP1B LC1 interact in a non-SCF manner, resulting in a functional modification of MAP1B LC1 
other than ubiquitination. It is interesting to note that MAP1B LC1 gets post-translationally 
modified through heavy phosphorylation by different kinases, two of which are of particular 
significance to this study. One of them is the LRRK2 also known as PARK8 but the functional 
significance of this modification remains to be determined (Chan et al., 2014). The other kinase to 
phosphorylate MAP1B is the glycogen synthase kinase 3  (Gsk3, and this phosphorylation has a 
major role in the regulation of microtubular dynamics in the growth cone especially during 
axonalpathfinding and regeneration (Goold et al., 1999; Liz et al., 2014). Intriguingly, Gsk3was 
also found to be a novel FBXO7-SCF interactor, leading to the ubiquitination of Gsk3, but the 
functional significance of this interaction was not further examined (Teixeira et al., 2016). 
Gsk3thusbecomes the only known link between FBXO7 and MAP1B prior to the results 
obtained by Dr. Brockelt. Another known modification of the MAP1B LC1 is its S-nitrosylation in 
the event of excessive intracellular nitric oxide (Yonashiro et al., 2012). This modification in turn 
promotes the mitochondrial MAP1B LC1 ubiquitination by the mitochondrial ubiquitin ligase 
MITOL, leading to its degradation (Yonashiro et al., 2012).  
4.4. Implications of FBXO7 and MAP1B LC1 in cellular morphology and 
mitochondrial homeostasis  
To further deepen our understanding about the functional importance and the cellular 
mechanisms in which FBXO7 and MAP1B LC1 interaction plays a role, I prepared lysates of cells 
overexpressing these proteins and the lysates were subjected to a mass spectrometry analysis at 
the RWTH Aachen Proteomics Facility. The results yielded a functional map with a total of 26 
candidates, representing up-regulated and/or overly stabilized proteins as a result of the MAP1B 
LC1 and FBXO7 interaction in comparison to MAP1B LC1 overexpressed with empty vector as 
control condition. These can be grouped in four major cellular niches, partially overlapping with 
the interactome network for FBXO7: DNA repair and transcription machinery, the UPS, the 
microtubular cytoskeleton, and mitochondrial homeostasis. The fact that the interaction resulted 
in overrepresentation of DNA-related proteins was quite striking, since there is no data linking 
MAP1B LC1 with these cellular complexes. It is possible that whilst performing its duties in the 





facilitate the transport of proteins and DNA. However, further research will be required to unravel 
the mechanism in which FBXO7 and MAP1B LC1 act together to ensure proper DNA repair and 
transcription. 
MAP1B carries the history of its discovery within its name- it was revealed because it would 
co-purify with microtubules (Bloom et al., 1985). The exact timing of its expression in rat neurons 
was determined to be highest in neonates, before dropping tenfold between postnatal days 10-20 
(Riederer et al., 1986). I wanted to check the expression of MAP1B LC1 in mouse neurons, to 
make sure that the experiments are conducted in cells that express the protein. Because the 
available antibody directed against endogenous MAP1B LC1 was unable to detect the protein 
neither on a western blot nor on cryosections (data not shown), I resorted to mouse cortical 
primary culture and immunocytochemistry. MAP1B LC1 is still strongly expressed throughout the 
neurons even after keeping them for 8 days in vitro which is consistent with the aforementioned 
findings.  
The main function of MAP1B is to promote axon outgrowth by stabilization of microtubules 
and regulation of the cytoskeletal assembly during early development (Gonzalez-Billault et al., 
2001). My findings however showed no role of FBXO7 in total axonal length, indicating that the 
functional significance of the MAP1B LC1-FBXO7 interaction takes place in a different context. A 
less studied function of MAP1B is its role in dendritic morphogenesis, even though MAP1B has 
been often observed in the dendrites (Bloom et al., 1985; Hirokawa, 1994; Ohyu et al., 1997). One 
study found MAP1B acting in synergy with MAP2 is indispensable for dendritic outgrowth (Teng et 
al., 2001). Interestingly, I found that upon knockdown of FBXO7 there was a decrease in the 
average total dendritic length as well as the average number of dendritic outgrowths from the 
soma. These findings may provide a functional link between FBXO7 and MAP1B specifically in 
their role to regulate dendritic density and morphology. 
Another group of proteins that were overrepresented in the quantitative mass spec analysis 
were oxidative-phosphorylation-related proteins, implicating the functional importance of the 
MAP1B LC1-FBXO7 interaction in mitochondrial homeostasis. Both proteins have been previously 
linked to mitochondrial health with several lines of evidence relating FBXO7 and mitochondria 
(Burchell et al., 2013; Teixeira et al., 2016). The earliest findings were paramount, because FBXO7 
was found to directly interact with two of the key PARK genes PINK1 (PARK6) and Parkin (PARK2)- 
the main initiators of mitophagy due to mitochondrial depolarization (Burchell et al., 2013). The 
authors found that upon mitochondrial depolarization, FBXO7 is translocated to the damaged 





proteins inaugurating mitophagy (Burchell et al., 2013). Moreover, the T22M and the R498X 
mutations resulted in the inability to recruit Parkin to the organelle and the R378G mutation 
prevented the ubiquitination of Mitofusin1 (Mfn1) (Burchell et al., 2013). Further research on 
mitochondrial viability and the Parkinson's disease-related Fbxo7 mutations revealed that the 
pathological forms of FBXO7 could aggregate in mitochondria, reducing the mitochondrial 
membrane potential and leading to increase in reactive oxygen species (ROS) formation and 
subsequently decreased cell survivability (Zhou et al., 2015). Additional insights into the 
pathophysiology of cells lacking FBXO7 substantiated the previous importance of FBXO7 in 
mitochondrial depolarization and ROS increase, stating that these are consequence of the 
depletion of nicotinamide adenine dinucleotide (NAD+) in the cell (Delgado-Camprubi et al., 2017). 
This in turn lead to a reduction of the NADH availability pool that is necessary for the proper 
complex I and consequently electron transport chain functioning (Delgado-Camprubi et al., 2017). 
Severe mitochondrial damage would result in the mitochondrial autophagosomal clearance, 
where mitochondria will have fragmented morphological phenotype (Youle and Narendra, 2011). 
I used this as readout for potential mitochondrial health and maintenance disruptions in FBXO7 
knockdown experiments. Although I observed no difference in mitochondrial morphology 
between the FBXO7 knockdown and control conditions in SH-SY5Y cells, I saw a significant 
increase in the number of HEK 293T cells with fragmented mitochondria. This increase appeared 
to be in a reverse correlation with the number of cells, containing tubular (healthy) mitochondria, 
indicating that indeed FBXO7 plays role in mitochondrial health in HEK 293T cells.  
 DJ-1 (PARK7) is found in the mitochondrial matrix and the intermembrane space, and it is 
recognized as a redox-sensitive molecular chaperone (Shendelman et al., 2004; Zhang et al., 
2005).  It was also recently found to directly interact with MAP1B, leading to the inhibition of the 
formation of MAP1B aggregates (Wang et al., 2011). As mentioned in the last paragraph in 
Section 4.3, S-nitrosylation of MAP1B LC1 is a functional modification leading to its selective 
ubiquitination and degradation of MAP1B LC1 by MITOL and the UPS respectively (Yonashiro et 
al., 2012). Interestingly, MITOL knockdown caused MAP1B LC1 to accumulate in mitochondria 
which further induced mitochondrial aggregation and cytotoxicity (Yonashiro et al., 2012). The 
authors proposed that S-nitrosylation causes MAP1B LC1 to translocate to microtubules thus 
stabilizing them (Yonashiro et al., 2012). This stabilization may also cause steric hindrance for the 
binding sites of motor proteins, in turn preventing any transport along the microtubules including 
mitochondrial transport (Yonashiro et al., 2012). MITOL then serves as a regulator of the 
microtubular stabilization by causing MAP1B LC1 degradation and reestablishing the normal 





ensures that all processes are transiently halted in the event of nitric oxide induced cytotoxicity 
(Yonashiro et al., 2012). In addition, the speed of mitochondrial retrograde transport along the 
axon is significantly increased in Map1b-/- neurons, further implicating that MAP1B may act as a 
competitor to the motor protein dynein for microtubule-site binding (Jimenez-Mateos et al., 
2006). To check if MAP1B LC1 also plays role in mitophagy, I used the same readout as for FBXO7 
knockdown, but I only saw significant decrease in the number of cells with tubular mitochondria 
in MAP1B LC1, which can still serve as a suggestion that MAP1B LC1 has a role in mitochondrial 
quality control mechanism. Interestingly, upon checking for MAP1B LC1 expression in SH-SY5Y 
cells, I was unable to detect signal in the immunocytochemical analysis, which can be due to one 
of the following reasons: either there is no MAP1B LC1 expression present in SH-SY5Y cells, or the 
antibody recognizes specifically mouse MAP1B LC1 but not its human orthologue. However, since 
mitochondria did exhibit some response to the knockdown of MAP1B LC1, the latter scenario 
seems more likely. 
These data taken together, might lead to a new possible neurodegenerative model in 
neurons, in which mitochondria located in the distal end of the axons are unable to translocate 
into the soma as part of the mitochondrial health maintenance pathways (Miller and Sheetz, 
2004). These mitochondria are subjected to high Ca2+, ATP-demand and reactive oxygen species 
formation, leading to mitochondrial damage (Fig. 4.1) (Brookes et al., 2004). In healthy neurons, 
they are transported back to the soma using microtubular tracks, where they can fuse with 
lysosomes- the end stage of mitophagy, maintaining a healthy mitochondrial pool  (Fig. 4.1). 
However, it is possible that in neurons lacking FBXO7, MAP1B LC1 gets functionally modified so 
that it hinders the binding sites for the motor proteins, rendering microtubular transport to a halt 
(Fig. 4.1). This in turn could lead to accumulation of aberrant and dysfunctional mitochondria, 







Fig. 4.1 Retrograde transport of mitochondria 
(A) In healthy neurons, mitochondria located at the synaptic terminus are exposed to high concentrations 
of reactive oxygen species (ROS) and Ca
2+
 and simultaneously they are burdened with a high demand of 
ATP. Damaged mitochondria are transported back to the soma with the help of dyneins, where they fuse 
with lysosomes as the final step of mitophagy takes place, ensuring that damaged mitochondria will  not 
generate an excess of reactive oxygen species (ROS). (B) If MAP1B LC1 is overly stabilized, it binds to 
microtubules thus blocking many of the dynein binding sites. This in turn leads to  a decrease of the rate of 
transport of damaged mitochondria. As a result, they cannot be cleared out and can potentially lead to an 





4.5. Mice lacking FBXO7 in the forebrain display generalized brain damage  
Vingill el al. published the first animal Fbxo7-/- model exhibiting a severe motor phenotype 
reminiscent of patient with parkinsonian pyramidal syndrome (PPS) and an average life 
expectancy of 21 days (Shojaee et al., 2008; Vingill et al., 2016). I further examined the 
consequences of Fbxo7 knockout in the forebrain as a part of a larger project aiming at breaking 
down the phenotypic spectrum of pathological symptoms according to the protein’s expression in 
different parts of the nervous system. There was no significant increase in apoptosis in the cortex, 
hippocampus nor the cerebellum in 8 week-old animals. However, there is a trend of increase in 
cell death in NEX-Cre;Fbxo7fl/fl  animals possibly due to the fact that the process had occurred 
previously in the forebrain but at the time of experimental examination, the cells were not 
undergoing active apoptosis. This possibility is quite likely for three reasons. First, both cultured 
neurons and in vivo analysis of the conventional Fbxo7 P18 knockout mice showed significant 
increase in the number of apoptotic cells (Brockelt, 2015; Vingill et al., 2016). Second, the gross 
cortex size area was significantly reduced in the NEX-Cre;Fbxo7fl/fl mice in comparison to the NEX-
Cre control and only as a trend in comparison to the Fbxo7fl/fl mice, even though the average body 
weight was analogous at this time point (Vingill et al., 2016). Third, there is a marked increase in 
the glial fibrillary acidic protein (GFAP) inflammatory marker signal, as well as the microglia-
specific Ionized calcium-binding adapter molecule 1 (Iba1) signal, implementing increased levels 
of astrogliosis and inflammation respectively. The relationship between astrogliosis, microgliosis 
and apoptosis can have different directionalities: brain damage caused by vascular insults or head 
injury as well as apoptosis caused by neurodegenerative diseases leads to increased astro- and 
microgliosis and vice versa, the induction of astro- or microgliosis through biological toxins causes 
apoptosis (Barreto et al., 2007; Hamby and Sofroniew, 2010; Herrera et al., 2000; Langston et al., 
1999; Samantaray et al., 2007; Xiong et al., 2011). Since the mice were neither treated nor were 
they subjected to head trauma, this phenotype is most likely due to early apoptosis caused by 
neurodegeneration. It is interesting to note, that even though Fbxo7 was not knocked-out in the 
cerebellum, there was also a marked increase of astrogliosis. The largest anatomical part of 
cerebellum is the cerebrocerebellum, whose major input arises from the corticobulbar tract as 
well as collateral axons form the corticospinal tract (Allen and Tsukahara, 1974). It is possible, that 
aberrations in the neuron's soma located in the cortex are projected through these tracts to the 
cerebellum, thus resulting in a secondary astrogliosis response. In conclusion, the NEX-
Cre;Fbxo7fl/fl mice exhibit a pronounced inflammation and astrogliosis on a histological level, 
which is mirrored in their significantly worse performance on a battery of motor tests, such as 





coordination, motor control and endurance are decreased and together with the observed 
spasticity, this animal model recapitulates the motor symptoms of PPS patients.  
Since a major hallmark symptom of PPS is pyramidal tract lesions, I studied the gross 
morphology of the pyramidal tracts in the NEX-Cre;Fbxo7fl/fl mice and observed no lesions or 
neurofilamentous tangles (Di Fonzo et al., 2009; Shojaee et al., 2008). It is possible that at this 
age, these aberrations are found on a molecular level only, and have not been detected at the 
time of experimental conduction. Next, I checked for the presence of -synuclein inclusions, but 
irrespective of the genotype, did not observe the formation Lewy body inclusions. Notably, both 
MAP1B LC1 and FBXO7 have been found in -synuclein inclusions (Jensen et al., 2000; Zhao et al., 
2013). Since Lewy bodies comprise of a plethora of proteins, I wanted to further test if FBXO7 and 
-synuclein would co-immunoprecipitate, but this interaction was not confirmed through cell- 
based co-immunoprecipitation. Furthermore, there is no Fbxo7-/- patient's data stating that Lewy 
bodies are part of the PPS pathology. 
4.6. Conclusion and Prospects  
         In this study, I confirmed that FBXO7 interacts with the microtubule associated protein 1B, 
and that it plays an important role in dendritogenesis and mitochondrial homeostasis. Further 
research will be necessary to show the exact molecular mechanism for the latter cellular process, 
more specifically if FBXO7 can influence the rate of retrograde transport of damaged axonal 
mitochondria.  
        The role of FBXO7 in neurodegeneration takes on two separate courses: one as part of the 
UPS and the second as the mitochondrial quality control machinery. These cellular mechanisms 
however are tightly interconnected since dysfunctions in one of these systems would lead 
inevitably to disturbances in the other creating a vicious circle that would ultimately l ead to 
cellular stress and death. 
        The findings in this study together with the known mechanisms involved in the 
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Table  A List of primer sequences used in this study and their corresponding number 
 Primer 
number 






15222 ATATGAATTCATATGAGGCTGCGGGTG pCMV-myc fwd 
15223 ATATGGTACCTCACATGAATGACAGCCGG pCMV-myc rev 
32501 ATAAAGCTTATGGTGGACCCGGAGGCGCTA MAP1S LC fwd 
29440 CTCGTCGACCTAGAACTCCACCTTGCAGGCC MAP1S LC rev 
32890 GATCCCCGGCCTCCCTGTGTATTTGGA 
TTCAAGCTTTCCAAATACACAGGGAGGCCTTTT 





















31215 GGGCTGTATGAAGGAAGTGCTATT FBXO7 wt, fwd 
31214 CCCTGAGAGTGAAGGGTGCTGTTC FBXO7 wt, rev 
04193-9 CAGGGTGTTATAAGCAATCCC Cre, fwd 







Table  B List of plasmid vectors used in this study 
Vector cDNA/shRNA Generated by 
pSUPER shFBXO7 #1 Siv Vingill 
pSUPER shFBXO7 #4 Siv VIngill 
pSUPER shFBXO7 #1 Guergana Dontcheva 
pSUPER shFBXO7 #3 Guergana Dontcheva 
pCMV-myc FBXO7 Madhuvanthi Kannan 
pCMV-myc FBXO7 T22M Siv VIngill 
pCMV-myc FBXO7 M115I Siv VIngill 
pCMV-myc FBXO7 R378G Siv VIngill 
pCMV-myc FBXO7 R598X Siv VIngill 
pCMV-myc FBXO7 N-terminus Siv VIngill 
pCMV-myc FBXO7 Ubl Siv VIngill 
pCMV-myc FBXO7 PRR Siv VIngill 
pCMV-myc FBXO7 FP Siv VIngill 
pCMV-myc FBXO7 C-terminus Siv VIngill 
pCMV-myc FBXO7 fbox Siv VIngill 
pCMV10-3xFLAG MAP1B LC1 David Brockelt 
pCMV10-3xFLAG MAP1B LC2 David Brockelt 
pCMV10-3xFLAG MAP1S LC Guergana Dontcheva 
pCMV10-3xFLAG FBXO7 Siv Vingill 
pRK-HA Ubiquitin Hiroshi Kawabe 
pcDNA3.0 FBXO7-FLAG Siv Vingill 
pcDNA3.0 Bcl-xL - 








List of all abbreviations used within this thesis: 
Abbreviation Spelled-out version 
oC Degrees Celsius 
aa Amino acid  
ADP Adenosine diphosphate 
ANOVA  Analysis of variance  
APP  Amyloid precursor protein  
APS Ammonium Persulfate 
ATP  Adenosine triphosphate  
ATP13A2 ATPase 13A2 
-gal -galactosidase 
Bcl-xL B-cell lymphoma-extra large 
BME Basal medium eagle 
bp Base pairs 
BSA Bovine serum albumin 
ca. circa 
Cdk6 Cyclin-dependent kinase 6 
cDNA Complimentary Deoxyribonucleic acid 










DIV  Day in vitro  
DMEM Dulbecco's modified eagle medium 
DmPI31 Drosophila melanogaster Proteasome inhibitor 31 
DNA  Deoxyribonucleic acid  
DTT 1,4-dithiothreitol 
dNTP Nucleoside triphosphate 
DTT  Dithiothreitol  
DUB  Deubiquitinating enzyme  
E1 Ubiquitin activating enzyme 
E2 Ubiquitin conjugating enzyme 
E3 Ubiquitin ligase enzyme 
EDTA  Ethylene-diaminetetraacetic acid  
ERAD  Endoplasmic reticulum-associated degradation  
FBXO7 F-box protein other 7 
FRT Flippase recognition target  
g gram 
GFAP Glial fibrillary acidic protein 
GFP Green fluorescent protein 
GSK3 Glycogen synthase kinase 3  
HA Hemagglutinin 
HBSS Hank's balanced salt solution 
HC Heavy chain 
HEK Human enbryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Het  Heterozygous  






HRP  Horseradish peroxidase  
HURP Hepatoma up-regulated protein 
IB Immunoblot 
Iba1 Ionized calcium-binding adapter molecule 1 
ICC Immunocytochemistry 
IgG(H/L) Immunoglobulin G (heavy/light chain) 
IHC Immunohistochemistry 
IP Immunoprecipitate 
IVS InterVening Sequence (intron) 
kb  Kilobase  
kDa  Kilodalton  
LC Light chain 
LRRK2 Leucine-rich repeat kinase 2 
M Molar 
MAP Microtubule associated protein 
Mfn Mitofusin 
mA Milli Ampers 
mg  Milligram  
μg  Microgram  
Miro Mitochondrial Rho GTPase 1 












NAD Nicotinamide adenine dinucleotide 
NEM N-ethylmaleimide 
NEX Neuronal basic helix-loop-helix  
NFM Neurofilament, medium 
ng  nanogram  
nm nanometer 
neo neomycin 
n.s.  non-significant  
OCT Ornithine-carbamyl transferase 
OOM Outer mitochondrial membrane 
P  Postnatal day  
PAGE  Polyacrylamide gel electrophoresis  
PARP Poly [ADP-ribose] polymerase 
PINK1 PTEN-induced putative kinase 1 
PBS  Phosphate buffered saline  
PCR  Polymerase chain reaction  
PD  Parkinson’s disease  
PFA  Paraformaldehyde  
PI31 Proteasomal inhibitor 31 
pmol picomol 
PPS Parkinsonian pyramidal syndrome 
PSG Penicillin, streptomycin, L-glutamine 
PSMA Proteasomal subunit  
PSMA2 Proteasomal subunit  






REM Rapid-eye movement 
RIPA Radioimmunopresipitation assay buffer 
RNA  Ribonucleic acid  
RNAi  Ribonucleic acid interference  
ROS Reactive oxygen species 
rpm  Revolutions per minute  
RT  Room Temperature  
SCF  Skp1, Cullin, F-box containing complex  
sec  Second  
SDS  Sodium dodecyl sulfate  
SDS-PAGE Sodium dodecyl sulfate-Polyacrilamide gel electrophoresis  
s.e.m. Standard error of mean  
Skp1  S-phase kinase-associated protein 1  
SNCA Synuclein,  
SNP Single nucleotide polymorpohism 
S.O.C. Super optimal broth with catabolite repression 
shRNA Short hairpin ribonucleic acid 
TAE Tris Base, Acetic acid, EDTA 
TEMED  Tetra-methyl-ethylene-diamine  
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
TdT Terminal deoxynucleotidyl transferase 
VPS35 Vacuolar protein sorting-associated protein 35  
v/v Volume per volume 
Ub Ubiquitin 
UbRD Ubiquitin-related domain 
UPS  Ubiquitin proteasome system  





wt Wild type  
w/v Weight per volume  
 
C Cysteine 
G Glycine 
K Lysine 
L Leucine 
M Methionine 
T Threonine 
Y Tyrosine 
X Stop 
 
A Adenosine 
G Guanine 
C Cytosine 
T Thymine 
 
 
 
 
